Download the 2015 annual report - University of Michigan Kellogg

UNIVERSITY OF MICHIGAN W.K. KELLOGG EYE CENTER
2015 ANNUAL REPORT
30
th Anniversary
~ Our Purpose ~
To improve lives
through curing,
preventing, and
treating eye disease
TEAMWORK
INTEGRITY
INNOVATION
CARING
Eye on the Future
University of Michigan Kellogg Eye Center Annual Report 2015
4
7
17
21
Kellogg Celebrates 30th
Advances in Education and
Anniversary
Patient Care
4
15 Kellogg Faculty Develop Digital
Learning Tools
Event at the U-M Museum
of Art Marks Milestone
6 Establishing the Qais A.
Farjo, M.D., Memorial
Lectureship
16 Residents Push Forward
Innovations and Research
22
Global Initiatives
22 Kellogg Hosts Third Annual
International Night
24 Helping an Ethiopian Hospital
Establish an Ophthalmology
Residency Program
18 Eye Care Goes Back to School
Vision Restoration and Research
7
Kellogg Hosts First Meeting
of Argus II® Retinal Prosthesis
System Investigators
9
Kellogg Scientists Brief Congress
on Vision Research
10 New Clinical Research Center
Offers More Trials
12 Kellogg Partners with U-M
Biointerfaces Institute to
Accelerate Therapeutic
Advances
19 Eye Clinic Expands at the VA
For patient appointments,
please call 734.763.8122.
Philanthropy in Support
Clinic phone numbers are
online under “Patient Care”
at www.kellogg.umich.edu
of Research
20 Kellogg Receives $3.5M Gift
from the Jerome Jacobson
Foundation
21 Updates on Glaucoma
Research at Kellogg
Front cover: David Antonetti, Ph.D.; Elizabeth Du, M.D.;
an image of the Kellogg Eye Center; Denise John, M.D.;
Tyson Kim, M.D., Ph.D.; an image of a 3D embryonic
stem cell culture from the lab of Robin Ali, Ph.D.; and
Courtney Dewey, O.D.
*This report covers the time period of July 1, 2014
through September 30, 2015.
Front row: Raymond Douglas, M.D., Ph.D., Shahzad Mian, M.D., and Denise John, M.D.
Back row: Alan Sugar, M.D., Michael Smith-Wheelock, M.D., Thomas Gardner, M.D., M.S., and Paul Lee, M.D., J.D.
The Chair’s Perspective
Dear Friends,
scientists are pursuing in collaboration with colleagues from
around the University. For example, among our new initiatives
This past fall, the University of Michigan Department of
Ophthalmology and Visual Sciences, founded in 1872, celebrat-
Institute. This collaboration has taken shape with three projects
ed the 30th anniversary of the W.K. Kellogg Eye Center. The
aimed at exploring novel methods of diagnosing types of ocular
construction of the Kellogg Tower in 1985 enabled our depart-
tumors and new treatments for diabetic retinopathy and macular
ment to unify offices, laboratories and clinical spaces that were
degeneration.
scattered across seven medical campus buildings. The opening
of the Brehm Tower in 2010 provided room for expansion and
opened in June 2015, provides dedicated space at Kellogg for
the opportunity to work more closely with leading diabetes
our investigators to conduct clinical research in all areas of
researchers. These tremendous facilities have enabled our fac-
ophthalmology. The KCRC team works with our faculty and
ulty, staff and trainees to work more effectively at shaping the
our volunteer patients to move clinical trials forward with the
future of vision science and eye care. Within these buildings, it
goal of evaluating the effectiveness of new treatments. Some of
is the teamwork and ingenuity of our people that have been the
our current trials involve assessing innovative therapies for age-
hallmarks of research, education and patient care at Kellogg.
related macular degeneration, investigating novel approaches
to treating cancer around the eye and examining a new therapy
In this year’s Annual Report, you will have the opportunity
to learn about some of the new ideas in research that Kellogg
2
is a joint project with investigators at the U-M Biointerfaces
The new Kellogg Clinical Trials Center (KCRC), which
for the treatment of dry eye disease.
At Kellogg, we realize that sharing information and
Introduction to Cataract Surgery for residents and trainees
experience means a faster path to improvement. As you may
who will perform cataract surgery. The course, which is free
recall from last year’s Annual Report, Kellogg retinal surgeons
of charge and offered globally, has run twice with 545 people
performed the first four Argus II Retinal Prosthesis System
in 131 different countries completing the instruction.
(Argus II) implantations in the United States since FDA approv-
al. To improve the Argus II patient experience, Kellogg hosted
this year was Devon Ghodasra, M.D., vitreo-retinal surgery
the first meeting of Argus II Investigators. Over 50 retinal sur-
fellow, who was awarded the Raymond R. Margherio Award
geons, researchers and rehabilitation professionals from around
for his research on vitreous cytokines. In addition, Thomas
the world who have worked with the implant, met to discuss
W. Gardner, M.D., M.S., Professor, was awarded the Retina
and share approaches, surgical and rehabilitation techniques
Society Award of Merit in Retina Research honoring Charles
®
Among those at Kellogg honored for their achievements
and outcomes. Five additional implantations have since been performed at
Kellogg. Worldwide, the Argus II has now
been implanted in over 130 patients in
29 centers in the United States, Europe
and the Middle East.
Expanding a commitment to global
initiatives, two of our faculty members
served as advisors in establishing a stateof-the-art residency training program for
ophthalmologists at the St. Paul Hospital
Millennium Medical College in Addis
Ababa, Ethiopia. The program, one of
only four in the country, began training
L. Schepens, which recognizes outstand-
“Together, we are partners
in solving eye disease and
are excited and eager to
accomplish even more in
”
the coming years.
ing national achievement in retina research.
Mark W. Johnson, M.D., Professor and
head of Kellogg’s Retina and Uveitis Service,
was elected to serve as the new president of
the Retina Society.
From developing new treatments and
educational innovations to cultivating leaders
in the field, the people of Kellogg have done
and continue to do much to advance the
visual sciences and the care of our patients.
In 2015, Kellogg had more than 163,000
patient visits and performed more than
—Paul P. Lee, M.D., J.D.
7,600 surgical procedures. As our patient
its first six residents last year. We are
volumes grow, we are more motivated than
excited to work with our Ethiopian colleagues to develop the
ever to achieve our goal of improving lives through curing,
program and an eye care center that will become a regional
preventing, and treating eye disease.
center of excellence. We also welcomed Thomas Lietman, M.D.,
Director of the F. I. Proctor Foundation, as our Center for
research and successes. You helped make the achievements
International Ophthalmology’s third Scholar-in-Residence,
of the last year and the last 30 years possible. Together, we
benefiting from his expertise in trachoma and other ocular
are partners in solving eye disease and are excited and eager
infectious diseases throughout the world.
to accomplish even more in the coming years.
We want to thank all who have contributed to our growth,
Two of our faculty members have developed innovative
ways to make information and training more accessible.
Jonathan Trobe, M.D., Professor, authored The Eyes Have It,
an educational app for iOS and Android, cataloging 134 eye
Paul P. Lee, M.D., J.D.
conditions, 410 images, more than 40 narrated animations and
F. Bruce Fralick Professor and
patient videos, six screening examination videos and an eye
Chair, Ophthalmology and Visual Sciences
anatomy review. Assistant Professor Elizabeth Du, M.D., has
Director, W.K. Kellogg Eye Center
developed a comprehensive four-week Coursera online class
30 Years of Service
Growing to better serve our
patients and expanding our
research to find new treatments
to cure blinding eye diseases.
PATIENT VISITS
19852015
36,852
163,232
SURGERIES
1,8257,681
FACULTY
1596
RESEARCH FUNDING
$0.9M
$14M
3
Mr. and Mrs. Dan Kachnowski share a toast.
Jerry May, Vice President of the U-M Office of Development,
chats with Thomas Varbedian, M.D.
Mr. and Mrs. John Breen, Jerome Jacobson Foundation.
KELLOGG CELEBRATES 30TH ANNIVERSARY
Marking an Important Milestone in
our Eye Center’s Growth and History
Mr. and Mrs. John R. Breen announced a $3.5M gift from
the Jerome Jacobson Foundation. “Jerome’s friends often heard
how Dr. Lichter, his longtime physician, assured him that with
proper management of his condition—through medication
Last fall, Kellogg celebrated its 30th anniversary with an event
and surgeries when necessary—he would have sight on the last
at the University of Michigan Museum of Art. Among our
day of his life. And he did,” says Mr. Breen, co-trustee of the
many honored guests were Paul A. Sieving, M.D., Ph.D., former
Foundation.
faculty member and founder of Kellogg’s Center for Retinal and
Macular Degeneration and current Director of the National Eye
Swaroop, Ph.D., former Kellogg faculty member and current
Institute at the National Institutes of Health; and Linh Nguyen,
Chief of the Neurobiology-Neurodegeneration and Repair
chief operating officer of the W.K. Kellogg Foundation.
Laboratory at the National Eye Institute, returned to give
the inaugural address of the Qais A. Farjo, M.D., Memorial
Paul R. Lichter, M.D., M.S., Founding Director of the
W.K. Kellogg Eye Center and former Chair of the Department
Earlier in the day, at Kellogg’s Fall Reunion, Anand
Lectureship.
of Ophthalmology and Visual Sciences for 34 years, highlighted
the remarkable growth and change during the last three decades.
For more information about these gifts, see pages 6 and 20.
Aisha Faridi, Amjad Ahmad, M.D., John Arendshorst, M.D., Linda Katz, M.D., and Douglas Katz, M.D., at the 30th anniversary event.
4
Paul Lichter, M.D., M.S., Paul Lee, M.D., J.D., and Linh Nguyen, COO, W.K. Kellogg Foundation.
Paul R. Lichter, M.D., M.S., at the podium.
“Our vision was for Kellogg to become
one of the finest eye centers in the
nation and that has been realized.
We now have the facilities and, more
importantly, the people to shape the
”
future of eye care and vision science.
— Paul R. Lichter, M.D., M.S.
James Woolliscroft, M.D., former Dean of the U-M Medical School,
shares a moment with Michael Staebler, J.D.
30th Anniversary celebration at the University of Michigan Museum of Art.
5
Kellogg faculty and alumni gather at Fall Reunion Day to celebrate the introduction of the first Qais A. Farjo, M.D., Memorial Lecture.
THE QAIS A. FARJO, M.D.,
MEMORIAL LECTURESHIP
A Fitting Tribute to One
of Our Department’s
Most Beloved Alumni
Anand Swaroop, Ph.D., and Paul A. Sieving, M.D., Ph.D., join in the celebration.
Anastas Farjo, M.D., Anand Swaroop, Ph.D., Muno Farjo, M.D.,
Rand Farjo, M.D., Deena Farjo, Rafid Farjo and Reem Farjo.
6
The Qais A. Farjo, M.D., Memorial
Lectureship was created through the generosity of those who were touched by Dr.
Farjo’s life and highlights his broad expertise in research, clinical care and education. The lectureship will
enable the Department to host speakers who will
share advances in their specialties, from translational research
to collaborative care, to innovative surgical techniques.
A remarkable physician, surgeon, researcher and mentor,
Dr. Farjo completed his medical degree, residency and fellowship at the University of Michigan before joining the faculty
of the Department of Ophthalmology and Visual Sciences.
Dr. Farjo is known for his contributions to basic research
through his characterization of the NRL gene, now known as
a master transcription factor governing photoreceptor cell fate
during development. He also served as medical director of
the Michigan Eye-Bank. Dr. Farjo died in February 2014
after fighting a courageous battle against cancer.
The inaugural address was given by Anand Swaroop,
Ph.D., former faculty member and Chief of the NeurobiologyNeurodegeneration and Repair Laboratory at the National
Eye Institute, during the 21st Annual Fall Reunion Day.
Kellogg hosts the first worldwide meeting of Argus II investigators.
WORLDWIDE NETWORK OF
ARGUS II® INVESTIGATORS JOIN FORCES
Collective Experience Draws Specialists
from Top Tier Institutions Around the World
challenges and reflect on what we’ve learned,” says K. Thiran
Jayasundera, M.D., Assistant Professor. “The need for open
communication is central—not just between different segments
of people in one institution, but across institutions—so that
In 2014, Kellogg retinal surgeons performed the first four
as a group we can refine this process that will ultimately benefit
Argus II Retinal Prosthesis System (Argus II) implantations
our patients.”
in the United States of an artificial retinal sensing device, or
“bionic eye,” which was approved in 2013 by the U.S. Food
favorable results, as well as new challenges. The event focused
®
and Drug Administration. Five additional
Initial experiences with the Argus II implant have delivered
on four areas of optimization—patient
implantations have since been performed at
“This was a significant event, the first
Kellogg. The device is intended for patients
of its kind, marking a critical juncture
rehabilitation and surgical technique.
blinding eye disease. Worldwide, Argus II has
for all of us to share experiences,
of an Argus II treatment, which starts with
now been implanted in over 130 patients in
highlight challenges and reflect on
screening patients to find the right fit to
the Middle East.
what we’ve learned.”
tations and the correct motivations,” says
— K. Thiran Jayasundera, M.D.
with retinitis pigmentosa, a degenerative and
29 centers in the United States, Europe and
In 2015, Kellogg hosted the first meeting
of Argus II Investigators, providing an oppor-
selection, device programming, visual
“The meeting covered the entire process
ensure that each patient has realistic expecByron L. Lam, M.D., Professor and Robert
Z. & Nancy J. Green Chair in Ophthalmol-
tunity for over 50 retinal surgeons, researchers and rehabilita-
ogy at the Bascom Palmer Eye Institute. “There were produc-
tion professionals to sit together in one room to discuss surgical
tive technical discussions particularly about how to make the
techniques and outcomes.
implantation more successful and how to avoid some of the
adverse events that can occur.”
“This was a significant event, the first of its kind, marking
a critical juncture for all of us to share experiences, highlight
7
Robert J. Greenberg, M.D., Ph.D., Chairman of Second
Optimizing visual rehabilitation
Sight Medical Products, the device manufacturer, noted that the
In visual rehabilitation, therapists help patients learn how to
meeting marks an important milestone. “This is the first time
interpret the new kinds of visual signals they perceive and then
that a critical mass from around the world is together sharing
incorporate them into daily activities. “To use the device to its
their great experiences with the technology,” says Dr. Greenberg.
fullest, patients must complete a two-pronged rehabilitation
“There is a real sense of excitement.”
program: in-clinic rehabilitation with an occupational or low
vision therapist and community rehabilitation with an orien-
Moving forward, Dr. Greenberg expects that the external
system for the next generation Argus II will be available in some
tation and mobility specialist,” says occupational therapist
markets worldwide beginning in late 2016.
Ashley Howson, M.S., OTR/L. “As part of the rehabilitation
process, therapists provide training and guided practice to help
Selecting the right patient
the patient learn how to use the device to increase independence
Genetic counselor and Assistant Research Scientist Kari E.
and quality of life with meaningful activities such as identifying
Branham, M.S., CGC, works with patients during the screening
where a loved one is standing, sorting laundry or detecting lines
process to see if they are candidates for the Argus II implant.
in a crosswalk.”
“A great deal of effort must be put into the patient selection
process. The process from pre-op to rehabilitation is rigorous
with the requirement of a series of visits,” says Ms. Branham.
“Completing a comprehensive evaluation by an occupational
therapist before surgery helps identify learning styles, cognitive
and physical impairments, psychological concerns, and to
continue conversations with patients about setting reasonable
goals, managing expectations and staying motivated throughout
the long rehabilitation process.”
Fine tuning the device programming
Electrophysiologist and Assistant Professor Naheed W. Khan,
Ph.D., assesses outcomes and works with device programming
at Kellogg. “If the patient is to perceive visual signals, the device
must be programmed correctly and adjusted over time,” says
Dr. Khan. “Device programming requires two to three sessions,
which can be arduous for the patient, but this step can determine the quality of visual performance and whether the patient
can use the device successfully.”
Evaluating surgical outcomes
Along with selecting the right patient, fine tuning the device
and optimizing visual rehabilitation, Dr. Jayasundera reflected
on some of the surgical variables that could improve patient
outcomes. “Based on a very small sample size, it appears that
younger patients may have better visual function after surgery,
possibly due to a healthier residual inner retina,” he explains.
“We also concluded that we may not need to exclude patients
with staphyloma, an abnormal protrusion of the uveal tissue via
a weakness in the eyeball, but rather should adapt our surgical
technique. Moreover, there is a need to develop surgical strategies to avoid hypotony, an intraocular pressure of 5 mm Hg or
less, and conjunctival erosion.”
Proposed modifications to the device include new glasses
and a vector processing unit with increased comfort, longer
battery life, improved ease of use, custom camera, improved
telemetry, faster processing and new filters.
THE ARGUS USERS' SUPPORT GROUP
In 2015, the Kellogg Argus II team hosted
the First Argus II® Retinal Prosthesis System
Users' Support Group. The meeting provided
a platform for our Argus II users to share their
experiences with the device with one another,
the Kellogg Argus II team, and engineers at
Second Sight, the device manufacturer.
Donna Chapman, Linda Schulte and Mary Hawkins at the
first Argus II® Retinal Prosthesis System Users' Support
Group held at Kellogg.
KELLOGG SCIENTISTS SELECTED
BY THE NATIONAL ALLIANCE FOR
EYE AND VISION RESEARCH TO
BRIEF CONGRESS
Rajesh Rao, M.D., (left) and Jason Miller, M.D., Ph.D., update members of the United States Congress.
Rajesh C. Rao, M.D., Assistant Professor, and postdoctoral
says Dr. Rao. “From gene therapy to stem cells to preci-
fellow and incoming resident Jason Matthew-Lewis Miller,
sion medicine, we have never been at a more promising time
M.D., Ph.D., were among 22 scientists selected to update
in translating cutting-edge technologies to patient care for
members of the U.S. Congress on ophthalmic science last fall
diseases such as age-related macular degeneration, diabetic
by the National Alliance for Eye and
retinopathy, inherited retinal degenerations
Vision Research (NAEVR) Emerging
“I am honored to represent young vision
Vision Scientists Program, a coalition of
scientists at Kellogg and across the coun-
55 professional, consumer and industry
and eye cancers.”
Dr. Rao explains that there remains a great
deal of work to do. “As the largest supporters
organizations involved in eye care. Drs.
try in our collective goal to highlight the
of vision research, our lawmakers, through the
Rao and Miller presented summaries
importance of vision research in finding
National Eye Institute, Departments of Defense
attended a House hearing on vision
new treatments and cures for blindness
the most important role in finding new cures
research and met with U.S. representa-
to our nation’s lawmakers.”
for blindness,” says Dr. Rao. “We want to assist
—Rajesh C. Rao, M.D.
loss from blinding eye diseases will worsen as
of their research to Congressional staff,
tives and senators to lobby for expanded
funding for the National Eye Institute.
“I am honored to represent young
and Veterans Affairs, and other agencies, play
them in budgeting for the future, since vision
our population ages. I hope that our advocacy
vision scientists at Kellogg and across the country in our collec-
will play a part in ensuring our nation’s future needs for our
tive goal to highlight the importance of vision research in finding
most valued sense—vision—which allows us to read, walk,
new treatments and cures for blindness to our nation’s lawmakers,”
drive, work, recognize faces and care for others.”
9
Grant Comer, M.D., M.S., examines Gwendolyn Rosier, a patient in his trial on treatments for proliferative diabetic retinopathy,
in the new Kellogg Clinical Research Center.
NEW CLINICAL TRIALS CENTER OPENS THE DOOR
FOR MORE STUDIES
In an effort to offer more clinical trials to patients, the Eye
The following stories highlight a few of our current trials.
Center recently opened its Kellogg Clinical Research Center
For a full list, visit: www.kellogg.umich.edu/research/open_
(KCRC)— 5,100-square-feet of dedicated space for investiga-
clinicaltrials.html
tors who conduct clinical research with resources to support
patient-oriented research studies in the specialties of retina,
cornea, glaucoma and pediatrics. Ocular oncology, oculoplastics and telemedicine projects are also included. Having
KELLOGG EXPLORES INVESTIGATIVE NEW TREATMENT
FOR WET MACULAR DEGENERATION
dedicated space for clinical trials frees the ophthalmology
Wet age-related macular de-
clinics from the complicated process of registering and
generation (AMD) is caused
examining clinical trial patients.
by the growth of abnormal
Grant M. Comer, M.D., M.S., Assistant Professor, leads
blood vessels beneath the
the eight-person KCRC team, who work with Kellogg faculty
macula, the part of the retina
and volunteer patients to move clinical trials forward with
that provides detailed, central
the goal of finding new treatments of high impact.
vision. These blood vessels
“We have seen tremendous progress in our ability to
are fragile and tend to hemor-
operate a wider range of clinical trials over the past year,” says
rhage or leak fluid, resulting
Dr. Comer. “From the addition of personnel with expertise in
clinical trial operations to the opening of the research space in
June, the KCRC, faculty scientists and our research volunteers
are already exploring the next generation of treatment options
available to our patients.”
Our current trials include a study to improve the treatment
of wet age-related macular degeneration, the investigation of a
new drug to treat cancer around the eye and the examination
of a supplement to treat dry eye disease.
10
in the formation of scar tissue
that can lead to permanent vision loss. Currently, the best treatment for wet AMD is injections of vascular endothelial growth
factor (VEGF) inhibitors, which have been shown to improve
vision rather than simply slowing the rate of vision loss. For
patients to reap the benefits of these injections, however, they
usually have to be done repeatedly.
Grant M. Comer, M.D., M.S., Assistant Professor, is
exploring a potential new treatment—encapsulated cell therapy
of the trial is to test whether this new drug will lead to improved
or ECT—that he hopes will replace these injections. The NT-
ophthalmic outcomes in patients suffering from BCCA around
503 ECT implant, about the size of a grain of rice, is surgically
the eye and to identify markers for tumor response.
placed into the eye under local anesthesia and contains tiny
capsules of cells that continuously release VEGF inhibitors to
the eye and can be disfiguring and blinding,” says Dr. Kahana.
the back of the eye to treat wet AMD.
“A clinical trial is needed to study how this innovative new drug
can be used to treat this cancer while preserving visual function.
Through this randomized study, Dr. Comer and his team
“Advanced basal cell carcinoma is commonly found around
will compare treatment with the NT-503 ECT implant to the
Given how common basal cell carcinoma is, and its potential
routine injections patients receive for wet AMD. “Clinicians
impact on vision, I’m pleased that such an important trial will
have been searching for ways to reduce the frequency of
be based at Kellogg and at U-M.”
injections into the back of the eye that are often required for
wet AMD,” says Dr. Comer. “This clinical trial will allow us
Kellogg plans to enter 50 patients over four years. Participation
to explore the safety and effectiveness of this new way of
in the study is for one year after initiation of the drug treatment.
delivering these medications.”
For more information, contact clinical research coordinator
Sonal Trivedi, M.S., CCRP, at [email protected].
The study is currently enrolling patients with the goal of
Enrollment for this trial is open to patients with BCCA and
six at Kellogg and 90 worldwide. Participation in this study
is for two years. Eligible patients must have active, wet AMD
KELLOGG EXPLORES SUPPLEMENTS AS TREATMENT
and have had a good response to previous injections of a VEGF
FOR DRY EYE
inhibitor drug (Avastin, Lucentis or Eylea). Kellogg is one of
Cornea specialist Roni M.
approximately 36 international sites participating in this study,
Shtein, M.D., M.S., Associ-
which is sponsored by Neurotech Pharmaceuticals, Inc. For
ate Professor, is leading the
more information, contact clinical research coordinator Pamela
Campbell, COT, CCRP, at [email protected].
Kellogg site of the Dry Eye
KELLOGG INVESTIGATES NEW DRUG TO TREAT
or DREAM, trial in hopes
Assessment and Management,
of finding a new treatment
CANCER AROUND THE EYE
option for a condition that
Vismodegib is a new drug
can cause severe ocular
recently approved by the
pain, corneal scars and ulcers,
U.S. Food and Drug Admin-
and loss of vision.
istration for treatment of
The DREAM study evaluates the safety and effectiveness
advanced or aggressive basal
of omega-3 fatty acid supplements to treat the symptoms of
cell carcinoma (BCCA), the
moderate to severe dry eye disease. These over-the-counter
most common type of eye
nutritional supplements are currently used to treat high levels
cancer, affecting approxi-
of fat in the blood.
mately 750,000 people in the
United States every year.
patients to seek care from their eye care professionals,” says
Oculoplastic surgeon Alon Kahana, M.D., Ph.D., Associ-
“Dry eye disease is extremely common and leads many
Dr. Shtein. “The DREAM study is the first major trial on dry
ate Professor, is leading a research team that aims to determine
eye disease that is not funded by a pharmaceutical company.
whether vismodegib can be used to preserve vital tissues around
We are excited to be a part of it.”
the eye as well as visual function in patients with BCCA. The
team also will perform basic and translational research on the
may extend their participation for an additional year. Dr. Shtein
response of cancer tissue to the drug. The clinical trial, termed
and her team hope to enroll 50 patients here at Kellogg, with a
VISORB (for VISmodegib for ORbital and periocular Basal cell
national goal of 600 patients. The trial is led by the University
carcinoma), was awarded a competitive research grant from
of Pennsylvania and funded by the National Eye Institute, a
Genentech, Inc., the manufacturer of vismodegib, which also
branch of the National Institutes of Health.
will provide the drug for the trial. Additional funding was
obtained from the U-M Head and Neck Oncology Program,
tor Munira Hussain, M.S., COA, CCRP, at hussain@med.
Kellogg and the U-M Comprehensive Cancer Center. The goal
umich.edu.
Participation in the study is for one year. Eligible patients
For more information, contact clinical research coordina-
11
KELLOGG SCIENTISTS
JOIN FORCES WITH U-M
BIOINTERFACES INSTITUTE
Collaboration Sparks Opportunities to
Accelerate Bench to Bedside Discoveries
Kellogg scientists partnered with the U-M Biointerfaces
Institute, a group of interdisciplinary biomedical researchers, at
a recent two-day conference to address barriers to solving thera-
Hakan Demirci, M.D., David Antonetti, Ph.D., and Rajesh Rao, M.D.
peutic challenges for patients with blinding eye diseases. The
B-EYE Biointerfaces Institute/Ophthalmology Challenge, a joint
initiative focused on how interactions in the life sciences, physi-
Dr. Antonetti will collaborate with Steven P. Schwendeman,
cal sciences and engineering can accelerate the development of
Ph.D., the Ara G. Paul Professor and Chair of the U-M Depart-
new drug delivery systems, was inaugurated at this conference.
ment of Pharmaceutical Sciences, to develop drug delivery de-
Belinda Seto, Ph.D., Deputy Director of the National Eye
vices for novel drugs that target vessel permeability in the retina,
Institute, delivered the keynote address Vision Breakthroughs
a problem in many leading vision-threatening diseases, including
diabetic retinopathy and age-related macular
Enabled by Multidisciplinary Approaches. The
“Collaborations with groups such
degeneration.
followed by breakout sessions where attendees
as the U-M Biointerfaces Institute
translate our findings into better therapies for
brainstormed ideas and concepts, identified
can provide important avenues that
our patients. Collaborations with groups such
orative research and seed fund proposals in the
allow us to turn our discoveries into
important avenues that allow us to turn our
categories of biomaterials and drug delivery,
novel treatments for eye diseases.”
discoveries into novel treatments for eye diseas-
—David A. Antonetti, Ph.D.
identified important signaling pathways and
event also included presentations by specialists in ophthalmology and biomedical sciences,
challenges, and designed next steps for collab-
microfluidics and sensors, cell and tissue engineering, and nanotechnology.
“One of our major goals at Kellogg is to
as the U-M Biointerfaces Institute can provide
es,” says Dr. Antonetti. “For example, we’ve
are developing inhibitors to control these path-
Three Kellogg faculty members were awarded
B-EYE grants
12
ways. Interactions with faculty like Dr. Schwendeman will allow
us to develop the best ways to deliver these drugs to patients.”
Rajesh C. Rao, M.D., Assistant Professor, received a chal-
Hakan Demirci, M.D., Associate Professor and Director of
lenge grant for his proposal Direct Reprogramming of Fibro-
Ocular Oncology, was the recipient of a challenge grant for
blasts into Photoreceptors by Defined Factors: A Novel Thera-
his proposal In-vivo Biopsy of Intraocular Tumors by Physio-
peutic Approach for Dry Age-Related Macular Degeneration,
chemical Photoacoustics. Dr. Demirci’s work seeks to aid in the
A Common and Untreatable Cause of Blindness. Dr. Rao will
differential diagnosis of intraocular tumors such as choroidal
work with Kellogg postdoctoral fellow Qiang Li, M.D., Ph.D.;
melanomas, hemangiomas and metastases. He is collaborating
U-M Department of Pathology research investigator Luis Villa
with U-M Department of Radiology research investigator
Diaz, Ph.D.; and Paul H. Krebsbach, D.D.S., Ph.D., the Roy H.
Guan Xu, Ph.D., to develop an ocular imaging system, called
Roberts Professor of Dentistry, Professor of Biomedical Engi-
photoacoustic imaging, a non-invasive, low cost imaging
neering, and Chair of the Department of Biologic and Materials
technology for structural and functional imaging.
Sciences and Division of Prosthodontics at the U-M School of
Dentistry. Dr. Rao will work with Dr. Krebsbach to reprogram
David A. Antonetti, Ph.D., Professor, was the co-recipient
of a challenge grant for his project Sustained Drug Delivery
skin cells to retinal cells without going through an intermediate
for Restoration of Blood Retinal Barrier in Macular Edema.
embryonic stem cell stage.
KELLOGG FACULTY AWARDED R01 GRANTS
David A. Antonetti, Ph.D., Pro-
fessor, has received the renewal of
in the RPE will identify additional ion channel genes that are
his NIH R01 grant Mechanisms
essential to keeping the photoreceptors healthy. “This research
of Retinal Vascular Permeability
is relevant as it will fill large gaps in our knowledge of how
in Diabetes. Dr. Antonetti studies
the healthy RPE works to sustain the photoreceptors and
the cellular mechanisms by which
may also shed new light on what causes retinal degeneration,”
endothelial cells, the cells that make
he says.
Dr. Hughes hopes that further research on ion channels
up blood vessels, proliferate and are
altered during diabetic retinopathy
and macular edema. Recent clinical
trials have demonstrated that targeting vascular endothelial growth factor (VEGF) can effectively
prevent progression of vision loss and, for some patients, restore
visual acuity. However, not all patients respond to anti-VEGF
therapies, which require repeated intraocular injections. Therefore, understanding how VEGF prevents vessel alterations is
critical.
Dr. Antonetti also studies inflammatory factors that are
elevated in patients with diabetic retinopathy. Understanding the
mechanisms underlying the effects of growth and inflammatory
factors, as well as proteins such as occludin that are involved in
vessel permeability, is expected to provide new insight into the
nature of blood vessel growth and maturation. “My ultimate
goal is to identify new targets for therapeutic intervention that
are effective against growth factors and inflammatory cytokines,” says Dr. Antonetti.
Thomas W. Gardner, M.D., M.S.,
Professor, and Steven F. Abcouwer,
Ph.D., Associate Professor, have
received the renewal of their NIH
R01 grant Regulation of Retinal Cell
Death in Diabetes. The ultimate goal
of their research is to develop treatments that will prevent vision loss in
persons with diabetes. This project
focuses on how diabetes impacts
the retinal neurons that provide vision. Recently developed anti-VEGF
therapies can limit damage in many
patients with advanced diabetic
retinopathy. These treatments are
employed late in the disease process,
when blood vessels are affected, but
do not address the earlier damage
to the neurosensory retina caused
Bret A. Hughes, Ph.D., Professor,
has received the renewal of his NIH
by diabetes.
Drs. Gardner and Abcouwer
R01 grant Ion Conductances in the
are continuing their studies, which identify novel pathways that
Retinal Pigment Epithelium. Dr.
cause dysfunction and death of these neurons, in the hope that
Hughes’ overall goal is to under-
therapies intervening at earlier stages of diabetes will prevent
stand how ion channels in the cell
severe damage. The specific goals of this study are to define
membranes of the retinal pigment
the role of proteins called “mechanistic target of rapamycin
epithelium (RPE) operate to maintain
complexes” (mTORC) in retinal neuron function and survival,
the salt and water balance of the
and to define the ways in which diabetes affects these protein
photoreceptor environment. Muta-
complexes to cause diabetic retinopathy. “We hope that under-
tions in several genes that encode ion
standing the mechanisms underlying changes in these protein
channels expressed in the RPE have been found to cause retinal
complexes will enable development of therapies to prolong the
degeneration, underscoring the crucial role that these membrane
survival of retinal neurons and prevent the onset of sight-threat-
proteins play in maintaining retinal health and integrity.
ening diabetic retinopathy,” says Dr. Gardner.
13
Alon Kahana, M.D., Ph.D., Sayoko Moroi, M.D., Ph.D., and Joshua Stein, M.D., M.S., all moved their inventions forward by filing for patents in 2015.
PATENTS FILED FOR INVENTIONS BY KELLOGG FACULTY
Automated Scalable Heat Shock Modification for Standard
Aquatic Housing Systems
the team of inventors developed a system that will display
Inventors: Alfonso Saera-Vila, Ph.D., Phillip E. Kish, Ph.D.,
and Alon Kahana, M.D., Ph.D.
Aquatic organisms are very useful for the experimental
study of human disorders. Changing the growth conditions
of aquatic model organisms, including water temperature and
pharmacologic exposure, is a very common research tool.
In order to improve the technology for changing tempera-
In order to better predict the outcome of MIGS procedures,
optical coherence tomography images that a surgeon can use
to select anatomical features, biomarkers and other features
of interest. The system can then translate the location of these
features to an en face image and generate a map used for surgical planning.
Magnetoelastic Actuator for Glaucoma Drainage Devices
ture (i.e. “heat shock”) or drug delivery to aquatic colonies for
Inventors: Yogesh B. Gianchandani, Ph.D. (U-M College of
experimental and drug-screening purposes, Kellogg’s team of
Engineering), Venkatram Pepakayala, M.S.E. (U-M College of
inventors developed a parallel manifold system with continuous
Engineering), and Joshua D. Stein, M.D., M.S.
water flow that reduces labor and improves reproducibility of
treatment conditions.
from the anterior chamber to an external reservoir, where a fi-
Glaucoma drainage devices (GDDs) divert aqueous humor
brous capsule forms about 4-6 weeks after surgery and regulates
Mapping of Internal Features on En Face Imagery
flow. GDDs have been successful in controlling intraocular pressure and preventing the worsening of glaucoma.
14
Inventors: Lawrence E. Kagemann, Jr., Ph.D., (University
of Pittsburgh), Joel S. Schuman, M.D., FACS (University
aqueous flow through the GDDs across the fibrous capsule
of Pittsburgh), and Sayoko E. Moroi, M.D., Ph.D.
around the end plate. To ease this resistance, the team invented
an enhancement to the GDDs using actuators with custom-
Minimally invasive glaucoma surgeries (MIGS) are a new
One issue with these devices has been the resistance to
classification of glaucoma procedures designed to lower the
ized geometries and 3D curvatures. These actuators, which are
pressure inside the eye. A major assumption of surgical success
remotely excited to resonance with a magnetic field generated by
is that abnormal resistance resides in the trabecular network
external coils, produce mechanical vibrations that can improve
and, once this resistance is bypassed, the outflow through
aqueous flow, prevent adhesion of scar tissue to the implant and
Schlemm’s canal and beyond is unimpeded. Outcomes, however,
facilitate removal of cells responsible for the development of
are not predictable and these procedures are performed with
dense fibrous tissues around the implant. By limiting scar tissue
no prior knowledge of the morphology of the patient’s aqueous
around the GDDs, the device can more effectively control the
humor outflow tract.
intraocular pressure.
KELLOGG BRINGS
COURSERA ONLINE
CLASS TO RESIDENTS
WHO WILL PERFORM
CATARACT SURGERY
Introduction to Cataract Surgery
Elizabeth Du, M.D., has developed a Coursera online class for ophthalmologists.
is Offered Globally, Free of Charge
Elizabeth Du, M.D., Assistant Professor, saw a need to make
learning the fundamentals of performing successful cataract
rated with Kellogg ophthalmologists from multiple specialties.
surgery more accessible to residents and trainees in the United
Comprised of weekly lectures by expert cataract surgeons, surgi-
States and worldwide.
cal video to demonstrate optimal performance of various steps,
weekly quizzes, and a pre-and-post-test, the course teaches the
To meet this need, Dr. Du developed a comprehensive
four-week Coursera online class Introduction to
To put together the comprehensive course, Dr. Du collabo-
fundamentals required to perform successful
Cataract Surgery. The course has run twice— in
“Each step, from preoperative
October 2014 and February 2015— with 545
evaluation to postoperative care,
extracapsular removal.
instruction and 2,610 people visiting the course
is covered to help prepare residents
ation to postoperative care, is covered to
site and watching at least a lecture.
and trainees for the operating
help prepare residents and trainees for the
the basics of cataract surgery on the Coursera
room, including intraocular lenses,
anesthesia, complications and challenging
platform for a number of reasons,” says Dr. Du.
anesthesia, complications and
cases,” says Dr. Du. “Since most cataract
and other trainees as they prepare to become
challenging cases.”
is imperative that the surgeon gain as much
cataract surgeons to have a comprehensive
—Elizabeth Du, M.D.
people in 131 different countries completing the
“We wanted to create a course to teach
“First, we thought it would benefit our residents
course delivered in a high-yield, high-impact
cataract surgery by phacoemulsification and
“Each step, from preoperative evalu-
operating room, including intraocular lenses,
surgeries are done with the patient awake, it
knowledge as possible prior to entering the
operating room.”
fashion. Second, we wanted to see what the interest in this type
Coursera provides universal access to the world’s best
of course was globally and if it would be an effective tool to
education, partnering with top universities and organizations
help those in developing countries to have a more accessible
to offer courses online.
training resource.”
THE EYES HAVE IT:
AN APP FOR iOS
AND ANDROID
A New Comprehensive
Pocket Resource for
Ophthalmic Information
Jonathan D. Trobe, M.D., Professor, saw the opportunity to provide greater resources to assist medical and optometric students
in learning about ophthalmology. To address this need, Dr. Trobe
authored The Eyes Have It, an app for iOS and Android comprising 134 eye conditions, 410 images, more than 40 narrated
animations and patient videos, six screening examination videos
and an eye anatomy review section.
“The text contains hyperlinks to supplemental images, narrated animations and videos that illustrate the clinical and teaching points. A picture-based, multiple-choice quiz allows users to
assess their knowledge,” says Dr. Trobe. A well-known educator,
Dr. Trobe is the author of The Physician’s Guide to Eye Care, now
in its 4th edition.
15
First-year resident Tyson Kim, M.D., Ph.D., captures an image of a patient’s retina with his new CellScope Retina device.
RESIDENT PURSUES INNOVATION IN IMAGING
With a background in physics and bioengineering, it is no
wonder that Tyson N. Kim, M.D., Ph.D., joined Kellogg’s
month before beginning his residency to screen diabetic patients
residency program with a promising project already in hand.
with the device. As he continues to gather data, he hopes to
“Kellogg was my top choice for residency because its support
prove that this technology can be used to screen for other blind-
for resident research and innovation is bar none,” says Dr. Kim.
ing eye diseases. Dr. Kim says that the next step is to collaborate
Upon starting his residency, Dr. Kim immediately benefitted
with physicians in the primary care setting to see if medical as-
from that support by enrolling in the House Staff Innovation
sistants can acquire images as high quality as those captured by
& Entrepreneurship Program. Designed for residents and
trained eye care professionals.
fellows at the University of Michigan and guided by experienced
instructors from across campus and in private industry, the
mary care physicians and other health care providers can use
34-week program provides participants with the tools and
to easily screen for several eye diseases,” says Dr. Kim. “This
resources needed to creatively address patient needs through
allows ophthalmologists to do fewer screenings while receiving
medical innovation.
far more referrals for disease treatment. Our hope is that health
care costs will be lowered, time saved and, most importantly,
Dr. Kim plans to continue work on the CellScope Retina
device born of a multi-institutional team including the lab-
To push the project forward, Dr. Kim came to Kellogg a
“We want to create a powerful, easy-to-use tool that pri-
that patients receive the vision care they need.”
oratory of Daniel A. Fletcher, Ph.D., at the University of
California, Berkeley, and Todd P. Margolis, M.D., Ph.D.,
To learn more about the residency program at Kellogg,
and Jeremy Keenan, M.D., M.P.H., at the University of
visit: www.kellogg.umich.edu/education/residency.html
California, San Francisco. The device enables a smartphone
to take high-quality, wide-field images of the retina by leveraging the high-resolution imaging, portability, computational
power and wireless data transfer capability of smartphones.
According to Dr. Kim, the implications of this technol-
ogy are far-reaching. For example, he points out that diabetic
retinopathy is one of the leading causes of preventable blindness
in the world, and nearly half of diabetic patients in the United
States fail to receive the recommended annual eye screening.
RANKED IN RESIDENCY
PROGRAMS
IN THE U.S.
#8
If more people can be screened by this device, more people can
be treated to prevent or delay vision loss from this disease.
16
2015 SURVEY BY DOXIMITY/U.S. NEWS & WORLD REPORT
Kellogg Resident Develops
Device to Make Eye Drops
Easier to Use
First-year resident Lev Prasov, M.D., Ph.D., researches a new angle-closure glaucoma gene.
RESIDENT WINS BRIGHTFOCUS
GRANT TO CONTINUE MEDICAL
SCHOOL RESEARCH
First-year resident Lev Prasov, M.D., Ph.D., chose Kellogg for his residency because of the broad support for research endeavors. Dr. Prasov, who earned a Ph.D.
from the U-M Department of Human Genetics, will now be able to complete a
research project he started during his fourth year of medical school with the help
of a $100,000 grant from the BrightFocus Foundation. He will study a newly
discovered angle-closure glaucoma gene.
The new gene, called MTRR, is involved in homocysteine metabolism. It was
discovered by studying a large family with iris cysts, which can block the fluid
outflow channels in the eye, leading to an increase in eye pressure and glaucoma.
Collaborating with Ruma Banerjee, Ph.D., Professor and Associate Chair in the U-M Depart-
“I was drawn to this project
ment of Biological Chemistry, and Rima Rozen,
because it offered a look into a
Ph.D., Professor of Human Genetics and
Pediatrics at McGill University in Montreal,
rare condition that has not been
Dr. Prasov will perform biochemical and
explored much in ophthalmology
functional studies on the protein that has been
changed by the mutation. The team will also
literature.”
study the role of the normal protein in the eye
—Lev Prasov, M.D., Ph.D.
and screen for mutations in the gene in patients
with the forms of glaucoma with which this biochemical pathway has been associated. Their findings will detail the role of the MTRR gene and its broader metabolic pathway in glaucoma and could lead to the development of future therapies.
“I was drawn to this project because it offered a look into a rare condition
that has not been explored much in ophthalmology literature,” says Dr. Prasov.
“More importantly, though, this project has given me the opportunity to work
with a large family and, based on our research, to possibly give them meaningful information about their condition. It’s very rewarding to be able to connect a
Prior to starting his residency, Marius A.
Tijunelis, M.D., M.B.A., spent a year at
Kellogg as an Innovation Fellow through
the U-M Medical Innovation Center. The
purpose of this fellowship was to invent,
develop and take to market a product
that would solve a common problem in
the field of ophthalmology.
Dr. Tijunelis and his colleague, David
Lorch, Ph.D., who was also an Innovation Fellow, designed and produced an
eye-drop-assist device, the DROPin™. The
device fits most types of eye drop bottles
and stabilizes the bottle for one-handed
use. Once the cap is removed, the bottle
is placed through the hole in the device.
The triangular end of the DROPin™ rests
on the bridge of the nose and the tip of
the bottle is centered over the eye. The
free hand is then used to hold open the
eye while the drop is applied.
In July 2013, the DROPin™ became
available for purchase on amazon.com,
at Kellogg’s Optical Shop and at a handful of pharmacies in the Ann Arbor area.
More than 500 DROPin™ devices have
been sold to date.
Now in his second year of residency, Dr. Tijunelis has noticed that many
patients have difficulty properly instilling
their medicated eye drops. “I believe
that this device helps patients accurately
instill their medications resulting in fewer
wasted drops and lower medication cost
over time,” says Dr. Tijunelis.
person to a research finding.”
17
Pediatric optometrist Courtney Dewey, O.D., examines patients at the Ypsilanti Community High School eye clinic.
EYE CARE GOES
BACK TO SCHOOL
services such as physical examinations, immunizations, laboratory testing and counseling.
Kellogg equipped the eye clinic for Dr. Dewey, who exam-
ines patients two Tuesdays per month, serving approximately
10 students per day. She initially worked through a backlog of
Kellogg Partners to Bring Vision
students who needed vision care. When the public schools are
Care Services to Underserved Areas
in session, Dr. Dewey has a steady stream of 7th through 12th
graders who come to the clinic if they are having visual symp-
A few years ago, Kellogg optometrist Courtney A. Dewey, O.D.,
toms or are referred by other members of the medical team.
spoke to Ypsilanti middle-school students about eye health. That
talk sparked a partnership between Kellogg and the University
Optical Shop staffers, who obtain the information from
of Michigan Health System (UMHS) Regional Alliance for
Mi-Chart, UMHS’ electronic medical records system, and ar-
Healthy Schools (RAHS) to establish an eye clinic at Ypsilanti
range for the eyeglasses to be manufactured. One of Kellogg’s
Community High School.
opticians then delivers the eyeglasses to the clinic in Ypsilanti.
RAHS, whose mission is to provide school-based health
If students need eyeglasses, Dr. Dewey notifies Kellogg’s
“RAHS is a great program that has really flown under the
programs and clinical services that improve the well-being of
radar,” says Dr. Dewey. “It’s a great example of how UMHS
students, their families and communities, was looking for a way
can help schools serve students and the community. Kellogg
to provide vision services to Ypsilanti’s underserved areas. Dr.
would love to eventually have a presence in all RAHS locations
Dewey knew Kellogg could help. In February 2015, the Com-
and to serve as a model for comprehensive school-based health
munity Eye Clinic opened as part of a newly-renovated, school-
centers statewide.”
based health center featuring a U-M medical team that provides
KELLOGG FACULTY MEMBER
RECOGNIZED FOR LEADING
OPHTHALMOLOGY AT THE
HOPE CLINIC
Providing Ophthalmic Care for the
Uninsured in Our Community
18
Paula Anne Newman-Casey, M.D., M.S., Assistant Professor, is
the recipient of the 2015 University of Michigan Medical School
(UMMS) Dean’s Award for Local Community Service for her efforts
as the director of the Hope@UMHS-KEC ophthalmology clinic program to provide ophthalmic care for the uninsured in Ann Arbor and
the surrounding areas.
"It is quite an honor to receive this award and I feel that it is
really a shared accomplishment with all of the faculty and staff from
the Kellogg Eye Center who have generously donated their Saturday
mornings to provide eye care for those in our community who do not
have insurance,” says Dr. Newman-Casey. “Over the last four years,
we have provided ophthalmic care to over 850 patients who would
have otherwise gone without. I know this program will continue into
the future because my colleagues are just that generous."
Recognizing UMMS faculty that have made extraordinary
contributions to the local, national or global community, this honor
carries a $5,000 discretionary academic award.
Innovative Safety CheckList Improves Quality of
Patient Care
Jennifer S. Weizer, M.D., director of the
Kellogg Quality Assurance team, recently
led efforts to devise an innovative safety
VA Chief of Ophthalmology Denise John, M.D., oversees the VA eye clinic.
EXPANDING AT THE VA
More Space, More Services to Care for Veterans
The University of Michigan Medical School and the VA Ann Arbor Healthcare System
(VA) have a decades-long history of collaborating to provide outstanding health care
to military veterans. Kellogg is the main eye care provider at the VA, where more than
90 patients per day are seen. To better handle growing patient volume, the VA eye
clinic recently underwent an expansion.
The renovated clinic increased in size from 10 to 17 exam lanes, all with updated
equipment. To improve patient flow, ophthalmology services have been moved to
one side of the clinic and optometry services are on the other. Kellogg has also gained
access to more operating room space 6-8 times per month.
In addition, Kellogg has added more providers so that there are now 20 physi-
cians providing VA care each week. To supplement comprehensive care, Kellogg offers
a different subspecialty clinic each day. The physicians are supported by a clinic supervisor, 11 ophthalmic technicians and six residents.
“In recent years, improving patient access while maintaining our high quality has
been our goal,” says Denise A. John, M.D., FRSCS, Assistant Professor and Chief of
Ophthalmology at the VA. “And with more providers, more exam lanes, more technicians and more surgery time, we are better able to meet the demands of our patients.”
Dr. John oversees the day-to-day operations of the eye clinic, including the residents
who complete two, seven-week rotations in each year of their training program. A
new feature is a resident continuity clinic, which allows two third-year residents and
four second-year residents to manage—with the appropriate level of faculty supervision—their own patients.
“The veterans are extremely appreciative of the care they receive,” says Dr. John.
“And we all work together as a team to put them first.”
checklist program for ophthalmologists to
use in the operating room before, during
and after surgery. Once it was put into
place, the team monitored surgical adherence to the checklist.
Results were shared with Kellogg
surgeons and staff and then educational
interventions were instituted, which led
to improved adherence rates.
“Collaboration and open communication among our surgical team were the
keys to improving adherence rates and
making the operating room an even safer
place for our patients,” says Dr. Weizer.
Upon completion of the checklist
project, Dr. Weizer worked with both the
University of Michigan Health System and
the American Board of Ophthalmology
Maintenance of Certification (ABO MOC)
programs to obtain approval for Kellogg
surgeons to earn ABO MOC credit for
their participation.
The ABO MOC program is a patientcentered, continuous professional development tool designed to assess and develop
the core competencies essential for providing high-quality patient care. Kellogg’s
checklist met the certification requirements
of Part 4 of the program—Demonstrating
Quality Improvement.
“This is the first program of its kind in
the country for which the ABO has granted
this type of credit,” says Dr. Weizer.
“More importantly, it improves patient
safety by making it easier for our faculty
to achieve the goals of the ABO MOC
program.”
19
KELLOGG IS RECIPIENT
OF $3.5M GIFT FROM
THE JEROME JACOBSON
FOUNDATION
Gift Establishes the Jerome Jacobson
Professorship and Vision Research Fund
Jerome Jacobson suffered from glaucoma for most of his life.
Paul Lichter, M.D., M.S., Paul Lee, M.D., J.D., and Mr. and Mrs. John Breen.
Diagnosed as a young adult, Mr. Jacobson’s vision presented
daily concerns and challenges for him. “In all the time I spent
with Jerry, I never knew a day or occasion where, at least in
Foundation with co-trustee Louis P. Rubinfield, a relative of Mr.
some way, sight didn’t come up,” says John R. Breen, longtime
Jacobson. “It is our hope that these endowments will ensure
friend and co-trustee of the Jerome Jacobson Foundation.
that the Eye Center continues to make strides toward eventually
“It was a serious fight he had with the disease.”
conquering glaucoma.”
In the early 1970s, just after relocating to Michigan,
Mr. Jacobson became a patient of Kellogg glaucoma special-
guished career as an economist, holding management posts for
ist Paul R. Lichter, M.D., M.S., Professor, a relationship that
both the Bendix Corporation and Burroughs Corporation in
endured until Mr. Jacobson passed away in 2008.
Michigan, and as president of Robert Nathan Associates, an
Mr. Breen describes Mr. Jacobson as a
economic consulting firm headquartered in
passionate philanthropist, supporting a long
“It is our hope that these endowments
list of causes with an eye toward fairness and
will ensure that the Eye Center contin-
Assistant Secretary for Economic Affairs in
the Kellogg Eye Center, which became a focus
ues to make strides toward eventually
Kennedy administration.
of the Foundation’s priorities over the past
conquering glaucoma.”
justice. One of his philanthropic causes was
seven years with major grants awarded for
basic research in glaucoma and international
—John R. Breen
Last year, the Jerome Jacobson Foundation awarded
Washington, D.C. He also served as Deputy
the U.S. State Department during the John F.
“As I came to know Mr. Jacobson over
more than 35 years, I began to realize that
he was a particularly careful and thorough
person in everything he did,” says Dr.
ophthalmology efforts.
20
Born in New Jersey in 1921, Mr. Jacobson built a distin-
Lichter. “The fact that he chose Kellogg as the institution
Kellogg a gift in the amount of $3.5M to support the establish-
where he would receive his glaucoma care was an important
ment of the Jerome Jacobson Professorship, a fully endowed
vote of confidence, especially after he relocated to Washington,
glaucoma professorship ($2.5M), and the endowed Jerome
D.C., yet continued to fly back to Michigan to see me regularly
Jacobson Vision Research Fund ($1M). The gift was announced
for his care. We became good friends.”
by Mr. Breen at Kellogg’s 30th Anniversary celebration held at
the University of Michigan Museum of Art.
philanthropy was as careful as his selection of medical care.
“Mr. Jacobson evaluated and thought about the causes that
“Jerry was a humble man. He was shy about putting his
Dr. Lichter explains that Mr. Jacobson’s approach to
name to his philanthropy and usually gave gifts anonymously.
he decided to support. His decision to support Kellogg was an-
This time, we wanted to endow a professorship in Jerome
other important endorsement,” says Dr. Lichter. “Mr. Jacobson
Jacobson’s name, highlighting his belief in the work that is done
considered Kellogg to be on the cutting edge of research and
at the Kellogg Eye Center, as he was deeply appreciative of the
patient care and an organization that has what it takes to find
treatment he received there,” says Mr. Breen, who directs the
better treatments, and even a cure, for glaucoma.”
UPDATES ON GLAUCOMA RESEARCH AT KELLOGG
Paula Anne Newman-Casey,
Philip J. Gage, Ph.D., Associate
M.D., M.S., Assistant Professor, has
Professor, studies Axenfeld-Rieger
created the eyeGuide, a counseling
Syndrome (ARS), a congenital
program supported by a web-based,
syndrome that is characterized by
tailored educational tool that ad-
abnormalities of the front part
dresses adherence rates to glaucoma
of the eye. Children with ARS
medications.
suffer from elevated intraocular
The program helps medical
pressure which can lead to early
assistants and technicians provide
onset glaucoma in over half of
high-quality, individualized patient
this young population.
counseling that might otherwise be
Unlike glaucomas that develop
possible only with an ophthalmologist. It begins by showing pa-
in adults, ARS is particularly resistant to conventional therapies
tients photographs of a healthy optic nerve, an optic nerve with
and surgical techniques. To address these challenges, Dr. Gage
glaucoma and their own optic nerve so that they can see the
and his team have generated a designer mouse model to study
disease progression. The eyeGuide also features patient stories
what Pitx2, a type of regulatory gene in the cell, does in the
to address specific issues such as the expense or side effects of
normal course of eye development. “We study the outcomes
glaucoma medications. It concludes with the development of an
when the lab genetically mimics what happens in patients who
action plan to help patients integrate taking glaucoma medica-
suffer from this disease,” says Dr. Gage. “One amazing find-
tions into their daily routine.
ing is that this model develops a similar ocular disease to what
humans develop, with alterations in the anterior ocular segment,
“At least one third of glaucoma patients do not take their
medications regularly, creating a significant segment of people
elevated intraocular pressure and optic nerve head cupping.”
who go on to develop needless vision loss,” says Dr. NewmanCasey. “We’ve found that this personalized approach really
Julia E. Richards, Ph.D., the
resonates with our glaucoma patients.”
Harold F. Falls Collegiate Professor
of Ophthalmology and Visual
Brenda L. Bohnsack, M.D., Ph.D.,
Sciences, and Sayoko E. Moroi,
Assistant Professor, is studying
M.D., Ph.D., Professor, have joined
the PAX6 gene and its mutations
the International Glaucoma
that are associated with aniridia,
Genetics Consortium to study
an eye disorder that leads to mal-
samples from more than 35,000
formation of almost all structures
subjects for genetic risk factors
of the eye. Approximately 50
associated with glaucoma.
percent of individuals with aniridia
“Through the use of genome-
have glaucoma and the disorder
wide technologies, this group identified four new genetic risk
can be difficult to treat and can
factors for elevated intraocular pressure, the only known
lead to significant vision loss and blindness.
modifiable risk factor for glaucoma,” says Dr. Richards.
“The group also provided data to confirm three other genetic
To learn more about PAX6, Dr. Bohnsack and her team
are collaborating with the U-M Human Embryonic Stem Cell
risk factors for glaucoma that are associated with elevated
Center. “We have human embryonic stems cells which were
intraocular pressure.”
derived from a family that is affected by aniridia and carries a
mutation in PAX6,” says Dr. Bohnsack. “We are characterizing
was invaluable to the study. “We were able to assemble a large
these mutant stem cells to better understand the role of this gene
enough study population to let us detect genetic risk factors that
in early human development and as a stepping-off point for
were not detectable in the smaller study populations assembled
creating potential stem cell treatments for those with aniridia.
by each of the separate research groups,” says Dr. Richards.
With this information, we can try to regenerate or reverse the
“The samples and data contributed by the group represented
dysfunctional tissue we see in this condition.”
more than 20 years of work by many doctors and researchers.”
Pooling the resources of many different research groups
21
H. Kaz Soong, M.D., Jonathan Trobe, M.D., Monte Del Monte, M.D., Thomas Lietman, M.D., Paul Lee, M.D., J.D., Christine Nelson, M.D., Timothy Johnson, M.D.,
and Joseph Kolars, M.D., at Kellogg's third International Night.
FORGING NEW RELATIONSHIPS IN
GLOBAL OPHTHALMOLOGY
The Kellogg Eye Center for International
Ophthalmology Facilitates International
Clinical and Research Activities
The Kellogg Eye Center for International Ophthalmology held
its third annual International Night on October 12, 2015.
The keynote speaker was 2015 Scholar-in-Residence Thomas
Lietman, M.D., the Ruth Lee and Phillips Thygeson Distinguished Professor and Director of the F. I. Proctor Foundation
for Research in Ophthalmology at the University of California,
San Francisco. The Foundation was established in 1947 with
the purpose of eradicating trachoma worldwide. Dr. Lietman
Thomas Lietman, M.D., and Zvi Kresch, M.D.
delivered a presentation Will the Last Case of Trachoma
Please Stand Up?
22
Dr. Lietman’s work centers around mass antibiotic distribu-
and infectious corneal ulcers, working in Egypt, Nepal,
tions for eliminating trachoma and the possible collateral effects
Ethiopia, India and Niger. Dr. Lietman has been the principal
of these distributions, including selecting for resistant organisms
investigator on several NIH-NEI and Gates Foundation random-
and impact on childhood mortality. “At the Proctor Founda-
ized trials. He is also part of the infectious disease modeling
tion, we’re looking for research questions where, if we are lucky
group at Proctor.
enough, an answer could have leverage and impact on a far
larger population,” says Dr. Lietman. “Whether that research
reasonable solution for controlling trachoma with mass anti-
is done in San Francisco— or Nepal, Ethiopia or South India—
biotic treatments and other measures. “I think we’re going to
that’s what we’re looking for.”
be able to control the disease to a level that the World Health
Organization currently sees as satisfactory,” says Dr. Lietman.
For the past 20 years, Dr. Lietman has studied trachoma
Dr. Lietman explained that, at the present time, there is a
Gurpreet Rana, MLIS, media specialist at the Taubman Health Sciences Library, speaks to
Tania Piotrowski, administrative director of U-M Global Reach, during International Night.
Roland Chen, Ph.D., Research Investigator at the U-M College of Engineering.
“I’m a little worried about what is going to happen after that.
members also teach abroad, so it’s really a very reciprocal
I don’t think trachoma is going to rebound and come back with
relationship.”
a vengeance if we stop control programs, but I do think we have
an opportunity to completely eradicate trachoma. And if we
medical student clerkship director, served as moderator for this
don’t jump on that opportunity now, I don’t think the resources
event. Presentations included: 1) An Academic Approach to
are going to be available in the future.
Ariane D. Kaplan, M.D., Instructor and ophthalmology
Global Health Engagement by Timothy
Trachoma could become a forgotten dis-
“I think the Kellogg Eye Center is perhaps
ease and linger on for a few decades if we
the leader in the educational aspect of
of the U-M Department of Obstetrics and
hand, trachoma could be the first bacterial
global health. Kellogg is really living the
Starting out in Global Health by Vicky
disease that we eradicate.”
idea that teaching goes both ways.”
Koski-Karell, M2; 3) Engineering Inno-
—Thomas Lietman, M.D.
Research in Ophthalmology by Roland
don’t stamp it out right now. On the other
Dr. Lietman expressed great admira-
tion for the scope of Kellogg’s international
program. “The Kellogg Eye Center for
R.B. Johnson, M.D., Professor and Chair
Gynecology; 2) Planting Rice in Haiti:
vations for Patient Care, Teaching, and
Chen, Ph.D., Research Investigator at the
International Ophthalmology has quickly become one of the
U-M College of Engineering; and 4) Kellogg in Ethiopia by
leading programs in the country. It’s difficult to believe that it
Zvi A. Kresch, M.D., Instructor.
has only been in existence for three years,” says Dr. Lietman.
“The Center has forged strong international collaborations with
top institutions on different continents. While I knew that the
U-M Department of Ophthalmology was one of the preeminent
departments in the world, this visit let me see how wonderful
the people are at this institution.”
Dr. Lietman commented on the components of global
outreach in academic health centers, including patient care, education and research. “I think the Kellogg Eye Center is perhaps
the leader in the educational aspect of global health,” he says.
“Kellogg is really living the idea that teaching goes both ways.
Residents at Kellogg, along with fellows and medical students
at the University of Michigan Health System, have the opportunity to travel to incredible locations and hospitals around the
globe to meet amazing physicians and surgeons who can teach
them about complex eye diseases. In turn, those physicians and
surgeons can come to to Kellogg to participate. Kellogg faculty
Donna Donato, administrative director of the Center for International Ophthalmology, Kellogg faculty member Christine Nelson, M.D., Dayakar Yadalla, M.D.,
oculoplastic surgeon and residency program director at the Aravind Eye Care
System (Pondicherry), and Kellogg faculty member César Briceño, M.D.
23
Jonathan Greene, M.D., (left), and Monte Del Monte, M.D., (right), with
Elias Hailu Gebreab, M.D., President of the Ophthalmological Society of Ethiopia.
Michael Smith-Wheelock, M.D., with Bezawit Tadegegne, M.D., Chair of Ophthalmology,
and Lemlem Tamrat, M.D., Director of the Ophthalmology Residency Program,
at St. Paul’s Hospital in Addis Ababa, Ethiopia.
KELLOGG TEAM HELPS ETHIOPIAN HOSPITAL ESTABLISH
A WORLD-CLASS RESIDENCY TRAINING PROGRAM
Jonathan B. Greene, M.D., Assistant Professor, and Monte A.
instrumental in elevating the quality of eye care not only in
Del Monte, M.D., the Skillman Professor of Pediatric Ophthal-
Ethiopia but in the entire East Africa region.”
mology, led the Kellogg team that has served as advisors to
St. Paul Hospital Millennium Medical College in Addis Ababa,
During the preliminary stages of development, Drs. Tadegegne
and Tamrat spent an intensive week at Kellogg visiting the
Ethiopia, in establishing a four-year residency
clinics and operating rooms, attending confer-
training program for ophthalmologists.
"We hope to assist our Ethiopian
ences and interviewing residents and faculty
Drs. Greene and Del Monte collaborated
colleagues in building a training
to find out how our program works. “We are
Tadegegne, M.D., and Ophthalmology
program and eye care center that
energy and determination to succeed in this
Program Director Lemlem Tamrat, M.D.,
will become a regional center of
critical enterprise in ophthalmic education,”
excellence.”
co-director of the Kellogg Eye Center for Inter-
with St. Paul’s Ophthalmology Chair Bezawit
in developing the new program, one of only
four such programs in Ethiopia.
“The first six residents began their train-
ing last September and we are excited to see
—Jonathan B. Greene, M.D.
how our faculty and experience with medical
impressed with the Hospital’s knowledge,
says Jonathan D. Trobe, M.D., Professor and
national Ophthalmology.
The initiative was spearheaded by Senait
Fisseha, M.D., Professor of Obstetrics and
education can be used to enable the growth of their program,”
Gynecology at the University of Michigan, who has had a major
says Dr. Greene. “We hope to assist our Ethiopian colleagues
role in developing training programs in obstetrics and gynecol-
in building a training program and eye care center that will
ogy, internal medicine, radiology and general surgery at St. Paul
become a regional center of excellence. Graduates will be
Hospital Millennium Medical College.
Since July 2014
43 INTERNATIONAL VISITORS TRAVELED FROM 16 DIFFERENT COUNTRIES
18 FACULTY MEMBERS TRAVELED TO 20 COUNTRIES WORLDWIDE
24
The University of Michigan A. Alfred Taubman Medical Research Institute is housed in the Biomedical Science Research Building.
TWO KELLOGG FACULTY ARE AWARDED TAUBMAN
MEDICAL RESEARCH INSTITUTE HONORS
Kellogg scientists and their laboratory groups work
Rajesh C. Rao, M.D., Assistant Professor,
steadily to find new treatments and cures for blinding
was appointed the Leslie H. and Abigail S.
Wexner Emerging Scholar by the University
eye diseases, such as diabetic retinopathy, age-
of Michigan A. Alfred Taubman Medical
related macular degeneration and retinitis pigmen-
Research Institute. Dr. Rao’s research focuses
tosa. The University of Michigan A. Alfred Taubman
on using stem cell biology and epigenetics
as languages to decipher the pathogenesis of
Medical Research Institute plays a key role in funding
our research initiatives.
retinal disease and future treatments. With
this award, he will receive support for his research for a period
of five years at $50,000 per year for the first three years and
Thomas W. Gardner, M.D., M.S., Profes-
sor, was named a Taubman Institute Scholar
by the University of Michigan A. Alfred
Taubman Medical Research Institute. Dr.
Gardner’s research focuses on understanding why diabetes damages the retina, with
the goal of helping people with the disease
maintain their vision.
$25,000 per year for the last two years.
“I am grateful for the transformative gift that Mr. and
Mrs. Wexner and the A. Alfred Taubman Medical Research
Institute have provided to further our work in finding new
ways to diagnose and treat blinding eye diseases,” says Dr. Rao.
“Their support will enable us to use epigenetics and stem cell
biology to better understand the basic biological mechanisms
that control stem cell behavior so that cells
With this honor, he will receive a three-
“It would be very difficult to conduct this
that are lost in blinding eye diseases can be
year renewable research grant of $50,000
early-stage work without the support of
collaborative, precision medicine efforts with
annually, followed by $5,000 per year
regenerated. Their gift will accelerate our
indefinitely.
the Taubman Institute. Mr. Taubman has
fellow Taubman Scholars to link patients
left an enduring legacy for which we are
treatments based on a tumor's unique genetic
“The Taubman Institute fosters high-
risk new ideas and this funding provides
with lethal diseases like eye cancer to targeted
the opportunity to determine if retinal func-
most grateful.”
and epigenetic profile.”
tion can be restored in people who have
—Thomas W. Gardner, M.D., M.S.
gram was created to support and encourage
diabetic retinopathy,” says Dr. Gardner.
“It would be very difficult to conduct this early-stage work
without the support of the Taubman Institute. Mr. Taubman
has left an enduring legacy for which we are most grateful.”
The Institute’s Emerging Scholars Proearly-career physician-scientists whose labo-
ratory work aims to translate basic research into new treatments
for disease. The program connects U-M Medical School faculty
members at the assistant professor level with philanthropists
who pledge to support the physicians’ research.
25
KELLOGG FACULTY
MEMBER LEADS SOCIETY
OF RETINAL SPECIALISTS
IN THE U.S.
Prior to taking over as president, Dr. Johnson served on the
Society’s executive committee for six years. He was elected secretary in 2009 and then served as treasurer and vice president.
Throughout his 25-year career, Dr. Johnson, who is a fellow of
the American Academy of Ophthalmology (AAO), has amassed
many accolades, including the AAO Honor Award (1995) and
the AAO Senior Achievement Award (2005). He was elected to
active membership in the American Ophthalmological Society in
2005 and is recognized in Best Doctors in America and Guide to
America’s Top Physicians. Dr. Johnson has served as the Associ-
For the first time in its history, the
ate Examiner for the American Board of Ophthalmology since
Retina Society and its 650 distin-
1995 and serves on the editorial boards of the American Journal
guished members are being led by
of Ophthalmology, Retina and Retinal Physician.
a Kellogg physician. At the 48th
annual meeting of the Society in
clinical research interests include pharmacotherapies for macular
Paris last year, Mark W. Johnson,
diseases and pathogenesis and treatment of vitreomacular
M.D., Professor, began his two-
interface disorders. Dr. Johnson served as principal investigator
year term as president.
and Data and Safety Monitoring Committee member for numer-
“It is a tremendous privilege
Dr. Johnson heads Kellogg’s Retina and Uveitis Service. His
ous national multicenter clinical trials in age-related macular
for me to have this opportunity
degeneration, retinal vascular disease and vitreoretinal disorders.
to serve my wonderful colleagues
He lectures widely on topics in macular and vitreoretinal disease
in the Retina Society who have
and has published over 175 articles and book chapters. Dr.
been huge sources of inspira-
Johnson completed medical school at the University of Utah in
tion throughout my career,” says Dr. Johnson. “I believe this
1984 and residency at Kellogg in 1988, serving as chief resident
appointment is, in part, an indication of the esteem with which
in his final year. He completed medical retina and vitreoretinal
ophthalmologists around the country regard the programs
surgery fellowships at the Bascom Palmer Eye Institute in 1990
and faculty of the Kellogg Eye Center and the University of
and then joined the Kellogg faculty as an assistant professor.
Michigan.”
KELLOGG RETINAL SPECIALIST AWARDED THE RETINA
SOCIETY AWARD OF MERIT IN RETINA RESEARCH
Thomas W. Gardner, M.D., M.S., Professor, is the recipient of the Retina Society
Award of Merit in Retina Research honoring Charles L. Schepens. This honor recognizes outstanding national achievement in
retina research and provides a $50,000
cash prize that includes $45,000 for
the recipient’s research and a $5,000
honorarium. The award was presented at
the annual meeting of the Retina Society
in Paris.
“The Award of Merit in Retina Research is greatly appreciated because
it is given by the Retina Society, a leading international organization of retinal
26
specialists,” says Dr. Gardner. “This award
recognizes the contributions of many
faculty members at the Kellogg Eye Center.
The funds from the prize will support additional research.”
The mission of the Retina Society is
to reduce worldwide visual disability and
blindness by promoting the education and
professional interaction of vitreoretinal specialists, providing optimal care for patients
with vitreoretinal diseases, and encouraging, through clinical and basic research,
the discovery and development of new
means to further patient care.
RESIDENTS AND FELLOWS
Department of Ophthalmology and Visual Sciences
Kellogg Fellow Awarded
the Retina Society’s
Margherio Award
Our residents and fellows are the future leaders in ophthalmology and
visual sciences. After training, most residents go on to fellowships at other
major institutions and our fellows pursue their subspecialties in private
practice or at academic medical centers. See where our 2015 graduating
residents and fellows are now:
2015 GRADUATING RESIDENTS
Courtney Y. Kauh, M.D., M.S.,
fellow in oculoplastics, University
of Wisconsin, Madison, Wisconsin
Mehnaz Khan, M.D., M.S.,
fellow in vitreo-retinal surgery,
Cleveland Clinic, Cleveland, Ohio
Lee M. Kiang, M.D., Ph.D.,
Graduate Chief Resident, Kellogg Eye
Center, Ann Arbor, Michigan
Matthew W. Manry, M.D., comprehensive ophthalmologist, Kellogg Eye
Center, Ann Arbor, Michigan. He will
enter a vitreo-retinal fellowship.
Catherine S. Choi, M.D., assistant
professor and pediatric ophthalmology
and strabismus specialist, Tufts
University, Boston, Massachusetts
Steven R. Cohen, M.D., retina
specialist, Retina Associates, PA,
Kansas City, Missouri
Marina A. Eisenberg, M.D., pediatric
ophthalmology and strabismus specialist, Cleveland Clinic, Cleveland, Ohio
Kristopher M. Kowal, M.D.,
neuro-ophthalmology specialist, Surrey
Memorial Hospital, Surrey, British
Columbia
Devon Ghodasra, M.D., Kellogg vitreoretinal surgical fellow, won the prestigious Raymond R. Margherio Award at
the 48th Annual Retina Society Meeting
in Paris last year for his research on
vitreous cytokines.
Established to support research into
macular disease and the development
of new technologies for macular surgery,
the fund supports an award to a vitreoretinal fellow of an active member of
Monica A. Michelotti, M.D., fellow
in vitreo-retinal surgery, Oregon Health
& Science University, Portland, Oregon
Andrew W. Lewis, M.D., glaucoma
specialist, U.S. Army, Wilford Hall
Ambulatory Surgical Center, San
Antonio, Texas
Melisa Nika, M.D., fellow in
glaucoma, Kellogg Eye Center,
Ann Arbor, Michigan
Steven G. Odaibo, M.S., M.D.,
retina specialist, Medical Associates,
Dubuque, Iowa
travel and lodging costs of attending the
Andrew W. Stacey, M.D., M.S.,
fellow in ocular oncology, Moorfields
Eye Hospital, NHS Foundation Trust,
London, England
Dolly A. Padovani-Claudio, M.D.,
Ph.D., assistant professor and pediatric
ophthalmology and strabismus specialist, Vanderbilt University, Nashville,
Tennessee
Fatemeh Rajaii, M.D., Ph.D., assistant
professor and oculoplastics specialist,
Johns Hopkins University, Baltimore,
Maryland
M.D., Ph.D.
2015 GRADUATING CLINICAL
FELLOWS
Victoria M. Addis, M.D., assistant
professor and glaucoma specialist,
University of Pennsylvania,
Philadelphia, Pennsylvania
Sejal Rajendra Amin, M.D.,
cornea specialist, Henry Ford Hospital,
Detroit, Michigan
Lulu Bursztyn, M.D., FRCSC,
assistant professor and neuro-ophthalmology specialist, Western University,
London, Ontario
Daniel Sand, M.D., cornea specialist,
Kaiser Permanente Medical Group,
Los Angeles, California
2015 GRADUATING RESEARCH
FELLOWS
the Society. Dr. Ghodasra was sponsored by Professor Thomas W. Gardner,
M.D., M.S. The award covered the
annual meeting, where Dr. Ghodasra
presented his research findings.
Dr. Ghodasra is Kellogg’s second
recipient of the Margherio Award, joining former fellow Edward F. Hall, M.D.,
who won the award in 2008 with the
support of Professor David N. Zacks,
FELLOWSHIPS AT KELLOGG
To learn more about the fellowship
opportunities at Kellogg, visit:
www.kellogg.umich.edu/education/
fellow.html
Mark T. Bolinger, Ph.D., Molecular
and Integrative Physiology, University
of Michigan, Ann Arbor
27
Brenda Bohnsack, M.D., Ph.D., and Joshua Stein, M.D., M.S., earn career development professorships to further their research.
KELLOGG FACULTY MEMBERS EARN PROFESSORSHIPS
TO ADVANCE THEIR PROMISING RESEARCH
28
Two of Kellogg’s most capable young faculty members earned
believes in bolstering the University's excellence as a whole.
career development professorships to advance their research.
He is a longtime supporter of the mission of the Kellogg Eye
Brenda L. Bohnsack, M.D., Ph.D., Assistant Professor, was in-
Center and served as chairman of the Community Advisory
stalled as the Helmut F. Stern Career Development Professor of
Board for Kellogg’s expansion campaign.
Ophthalmology and Visual Sciences, and Joshua D. Stein, M.D.,
M.S., Associate Professor, was installed as the Edward T. and
Cataract, and Anterior Segment Disease Service, heads Kellogg’s
Ellen K. Dryer Career Development Professor in Ophthalmol-
Center for Eye Policy and Innovation, which performs cutting-
ogy and Visual Sciences. Both professorships were established to
edge research that translates billions of individual data points
provide junior faculty with important research support and are
into results that can ultimately save patients’ vision and improve
held for five years.
their lives.
Dr. Bohnsack, a member of the Pediatric Ophthalmology
Joshua D. Stein, M.D., M.S., a member of the Glaucoma,
“I am enormously grateful to the Dryer Charitable Foun-
and Adult Strabismus Service, as well as the Glaucoma, Cata-
dation for supporting our ongoing efforts to push technologi-
ract, and Anterior Segment Disease Service at Kellogg, special-
cal boundaries with the ultimate aim of improving the quality
izes in the medical and surgical management of congenital
and affordability of eye care and patients’ access to it,” says
eye diseases. The goal of her research is to create molecularly
Dr. Stein. “Edward and Ellen Dryer’s beautiful decades-long
targeted therapies to cure these diseases.
partnership and their respective pioneering careers will provide
meaningful inspiration as my colleagues and I forge ahead
“This professorship will allow me to continue my work in
understanding the basis of congenital eye diseases in the hopes
with exciting collaborative research projects.”
of applying this knowledge to prevent childhood blindness,”
says Dr. Bohnsack.
from Dartmouth Medical School in 1997 and his M.D. from
Thomas Jefferson University in 2001. He completed his residen-
Dr. Bohnsack earned her Ph.D. in molecular and cellular
Dr. Stein earned his M.S. in Evaluative Clinical Sciences
biology in 2004 and her M.D. in 2006 from the Baylor Col-
cy at New York University (2005) and a Glaucoma fellowship
lege of Medicine. She went on to complete her residency (2010)
at Duke University (2007). Dr. Stein joined the faculty at Kellogg
and a postdoctoral fellowship (2011) at Kellogg and a Pediatric
in 2007 and then earned a second M.S. in Health and Health
Ophthalmology and Adult Strabismus fellowship at Duke
Care Research at U-M in 2010.
University (2012). Dr. Bohnsack then returned to Kellogg to
join the faculty.
Foundation, which was formed through the estate of the Dryers,
who lived in Detroit and passed away within months of each
The Stern Professorship, previously held by Alon Kahana,
The Dryer Professorship was established by the Dryer
M.D., Ph.D., Associate Professor, was established by Mr. Stern,
other in 2010. Mr. Dryer, an international banking executive,
an Ann Arbor businessman and philanthropist. Mr. Stern grew
was struck with blindness in the middle of his career. Mrs. Dryer
up in Germany and settled in Ann Arbor in 1942, where he
was an advertising pioneer who served as the first woman media
served as president of Industrial Tectonics and later as president
director at W.B. Doner & Company. The Dryer Professorship
of Arcanum Corporation. Mr. Stern generously supports numer-
was previously held by Grant M. Comer, M.D., M.S., Assistant
ous schools and projects at the University of Michigan and
Professor.
Meet Kellogg’s New Faculty
Angela R. Elam, M.D., clinical lecturer, has
joined the faculty of the Glaucoma, Cataract,
and Anterior Segment Disease Service and
sees patients in Kellogg’s Northville and
Ypsilanti offices. Dr. Elam earned her medical
degree from Duke University and completed
her residency at the University of Pittsburgh.
She then completed her fellowship in glaucoma at Kellogg. Dr. Elam’s research focuses
on disparities in eye care, eye care utilization and health services.
Yannis M. Paulus, M.D., assistant professor, has joined the faculty of the Retina and
Uveitis Service and sees patients in Kellogg’s
Grand Blanc office. Dr. Paulus earned his
medical degree and completed his residency
at Stanford University. He then completed a
medical and surgical vitreoretinal fellowship
at the Wilmer Eye Institute of Johns Hopkins
University. Dr. Paulus holds a joint appointment in the U-M Department of Biomedical Engineering and his
research focuses on the development of novel retinal imaging
systems and therapeutic techniques and technologies, including
photoacoustic imaging, molecular imaging, restorative retinal
laser therapy and surgical techniques.
Julie M. Rosenthal, M.D., clinical instructor, has joined the faculty of the Retina and
Uveitis Service and sees patients in Kellogg’s
Grand Blanc office as well as at the VA
Ann Arbor Healthcare System. Dr. Rosenthal
earned her medical degree from the University
of Pennsylvania and completed her residency
at the Wills Eye Institute of Thomas Jefferson
University. She completed her fellowship in vitreoretinal surgery at the Casey Eye Institute at the Oregon Health &
Science University and, before joining Kellogg, Dr. Rosenthal served
as a retinal specialist at Retinal and Ophthalmic Consultants, P.C.,
in Northfield, New Jersey.
Manjool Shah, M.D., clinical instructor,
has joined the faculty of the Glaucoma,
Cataract, and Anterior Segment Disease Service and sees patients in Kellogg’s Ann Arbor
and Grand Blanc offices. Dr. Shah earned his
medical degree from Washington University
in St. Louis and completed his residency at
the Casey Eye Institute at the Oregon Health
& Science University. He then completed
a fellowship in glaucoma and advanced anterior segment surgery
at the University of Toronto.
Upcoming CME Programs
Each year, Kellogg offers an informative series of continuing
medical education programs designed to share new approaches to the diagnosis and management of eye disease across
subspecialties. Below are our upcoming programs:
Saturday, March 12, 2016
Tri-City Regional Update Conference
9 a.m. – noon
The Conference Center at Apple Mountain
Freeland, Michigan
Application will be submitted for 3.0 AMA PRA Category 1
continuing medical education credits
Friday, September 30, 2016
22nd Annual Fall Reunion Day
8 a.m.– 4:15 p.m.
Kellogg Eye Center
Ann Arbor, Michigan
Friday, June 10 – Saturday, June 11, 2016
88th Annual Spring Postgraduate Conference
and 32nd Annual Research Day
8 a.m.– 5 p.m.
Kellogg Eye Center
Ann Arbor, Michigan
Application will be submitted for 5.5 AMA PRA Category 1
continuing medical education credits.
Application will be submitted for 15.0 AMA PRA Category 1
continuing medical education credits.
For questions, contact Jennifer Burkheiser, CME Coordinator,
at 734.763.2357 or [email protected].
For more information or to register for these programs,
visit: www.kellogg.umich.edu/education/cmeoverview.html
29
FACULTY HONORS AND RECOGNITION
JULY 1, 2014 — SEPTEMBER 30, 2015
David A. Antonetti, Ph.D.
Monte A. Del Monte, M.D. (cont.)
Editor, Tissue Barriers
Grant Reviewer, Scientific Advisory Committee, National Priorities
Study Section, Diseases and Pathophysiology of the Visual System,
Research Program, Qatar National Research Fund
National Institutes of Health
Section Chair, Editorial Committee for Eye Wiki Online Encyclopedia,
Steven M. Archer, M.D.
Best Doctors in America
Castle Connolly Top Doctors
Senior Achievement Award, American Academy of Ophthalmology
Cagri G. Besirli, M.D., Ph.D.
Best Doctors in America
Top 40 under 40 Power List, The Ophthalmologist
Commercial Relationships Committee, Association for Research
in Vision and Ophthalmology
Jill E. Bixler, M.D.
Best Doctors in America
Brenda L. Bohnsack, M.D., Ph.D.
Best Doctors in America
César A. Briceño, M.D.
Best Doctors in America
Grant M. Comer, M.D., M.S.
Best Doctors in America
Theresa M. Cooney, M.D.
Best Doctors in America
Regional Director, Michigan Society of Eye Physicians and Surgeons
Wayne T. Cornblath, M.D.
Best Doctors in America
Lindsey B. De Lott, M.D.
Best Doctors in America
Monte A. Del Monte, M.D.
America’s Top Doctors
Castle Connolly Top Doctors
Life Fellow, American Academy of Ophthalmology
Lifetime Achievement Award, American Association for Pediatric
Ophthalmology and Strabismus
Chairman and Annual Meeting Organizer, American Association
for Research in Strabismus
Fellowship Directors' Committee, American Association for Pediatric
Ophthalmology and Strabismus
Grant Reviewer, Scientific Review Committee, Medical Advisory Board,
Knights Templar Eye Research Foundation
30
American Academy of Ophthalmology
Section Chair, Pediatric Ophthalmology and Strabismus, American
Academy of Ophthalmology
Senior Consultant, International Affairs Committee, American Association
for Pediatric Ophthalmology and Strabismus
Vice President and President-Elect, The Costenbader Pediatric
Ophthalmology Society
Hakan Demirci, M.D.
Best Doctors in America
Senior Achievement Award, American Academy of Ophthalmology
Anwar Shah Retina Lecture, Alumni & Residents Day 2015, Department
of Ophthalmology, St. Louis University
Raymond S. Douglas, M.D., Ph.D.
Best Doctors in America
Susan G. Elner, M.D.
Best Doctors in America
Victor M. Elner, M.D., Ph.D.
Best Doctors in America
Castle Connolly Top Doctors
Jerome I. Finkelstein, M.D.
Best Doctors in America
Patrice E. Fort, Ph.D., M.S.
Academic Editor, Ophthalmology Research: An International Journal
Editorial Board, Journal of Clinical and Experimental Ophthalmology
Grant Reviewer, Research Grant Review Committee, American
Diabetes Association
Grant Reviewer, "Societal challenges” Grant Applications,
French National Research Agency
Grant Reviewer, “Tender offers” Grant Applications, Institut Carnot
Voir et Entendre, Paris, France
Bruce A. Furr, C.O., Ph.D.
Lancaster Medal, American Association of Certified Orthoptists
Board of Directors, Foundation for Orthoptic Research in America
Christopher Gappy, M.D.
Best Doctors in America
Rules and Bylaws Committee, American Association for Pediatric
Ophthalmology and Strabismus
FACULTY HONORS AND RECOGNITION
JULY 1, 2014 — SEPTEMBER 30, 2015
Thomas W. Gardner, M.D., M.S.
Paul P. Lee, M.D., J.D.
Best Doctors in America
Best Doctors in America
Gold Fellow, Association for Research in Vision and Ophthalmology
Castle Connolly Top Doctors
Associate Editor, Diabetes
Editorial Board, JAMA-Ophthalmology
Grant Review Panel, American Diabetes Association
Advisory Board, Hoskins Center for Patient Safety and Quality,
The Retina Society Award of Merit in Retina Research
Foundation of the American Academy of Ophthalmology
Charles L. Schepens Lecture, The Retina Society Annual Meeting
Board of Directors, American Board of Ophthalmology
3rd Joseph Sassani Alumni Lecture, Department of Ophthalmology,
Board of Governors/Immediate Past Chair, Association for
Penn State College of Medicine
Research in Vision and Ophthalmology Foundation
Hilary M. Grabe, M.D.
Best Doctors in America
John R. Heckenlively, M.D.
Best Doctors in America
Castle Connolly Top Doctors
Associate Editor, Eye
Editorial Board and Founding Editor, Documenta Ophthalmologica
Grant Reviewer, National Institutes of Health
Grant Reviewer, Foundation Fighting Blindness
Grant Reviewer, Fight for Sight
K. Thiran Jayasundera, M.D.
Top 40 under 40 Power List, The Ophthalmologist
Denise A. John, M.D.
Best Doctors in America
Mark W. Johnson, M.D.
Best Doctors in America
Castle Connolly Top Doctors
President-Elect and Vice President, The Retina Society
Editorial Board, American Journal of Ophthalmology, Retina,
and Retinal Physicians
Scientific Program Chair, The Retina Society Annual Meeting 2015
Mark J. Daily Retina Lecture, Department of Ophthalmology,
Loyola University
Alon Kahana, M.D., Ph.D.
Best Doctors in America
Editorial Board, Oculoplastic Surgery Section, Ocular Surgery News
Editorial Group, Basic and Clinical Science Course, Section 2:
Fundamentals, AAO Publications
Physician-Scientist Award, Research to Prevent Blindness
Joan & Gordon Bergy, M.D. Lecture in Vision Science, “Gained in
Translation” Vision Conference, University of Washington
8th Annual M. Bruce Shields Lectureship, Yale University
American Glaucoma Society Lecture, American Glaucoma Society
Annual Meeting
Robertson Lecture, University of Texas Medical Branch
Shaffer-Hetherington-Hoskins Lecture, 19th Annual Glaucoma Symposium,
Glaucoma Research Foundation
J. Britto Distinguished Lecture, University of Sao Paulo, Sao Paulo, Brazil
Paul R. Lichter, M.D., M.S.
Best Doctors in America
Castle Connolly Top Doctors
Associate Editor, American Journal of Ophthalmology
Foundation Board of Directors, International Council of Ophthalmology
Knauer Lecture, American Eye Study Club
Fralick Lecture, Department of Ophthalmology, University of Michigan
Michael J. Lipson, O.D.
Secretary, Scleral Lens Education Society
Shahzad I. Mian, M.D.
Best Doctors in America
Castle Connolly Top Doctors
Editorial Board, Cornea
Guest Editor, Current Opinion in Ophthalmology
Board of Directors, Cornea Society
Board of Directors, Eye Bank Association of America
Co-Chair, Cornea Sub-specialty Day, American Academy of
Ophthalmology
Council Credentials Committee, American Academy of Ophthalmology
Medical Director, Eversight Michigan
Program Directors Council, Association for University Professors in
Ophthalmology
Vice Chair, Accreditation Board, Eye Bank Association of America
Vice Chair, Residency Review Committee, Accreditation Council for
Graduate Medical Education
Senior Achievement Award, American Academy of Ophthalmology
31
FACULTY HONORS AND RECOGNITION
JULY 1, 2014 — SEPTEMBER 30, 2015
Sayoko E. Moroi, M.D., Ph.D.
Donald G. Puro, M.D., Ph.D.
Best Doctors in America
Best Doctors in America
Cohen-Merck Lecture, 37th Midwest Glaucoma Symposium,
Indiana University School of Medicine
Rajesh C. Rao, M.D.
David C. Musch, Ph.D., M.P.H.
Delegate, Congressional Briefing and Emerging Vision Scientists
Editorial Board, Eye and Vision
Reception, National Alliance for Eye and Vision Research Emerging
Editorial Board, JAMA Ophthalmology
Vision Scientists Program
Editorial Board, Retina
Editorial Panel, Innovative Retina Surgical Video Series, American
Advisory Group, Cochrane Collaboration Eyes and Vision Group
Society of Retina Specialists
US Project
Ophthalmic Technology Assessment Committee, American Academy
of Ophthalmology
Preferred Practice Patterns Committee, American Academy of
Ophthalmology
Review Committee, Prevent Blindness Joanne Angle Investigator Award
Grant Application Reviewer, Special Emphasis Panels, National
Institutes of Health
Scientific Reviewer, Health and Medical Research Fund and Innovation
and Technology Support Programme, Government of the Hong Kong
SAR, People’s Republic of China
Scientific Reviewer, National Medical Research Council, Government
of Singapore
Chair, Data and Safety Monitoring Committee, Corneal Preservation
Time Study, National Institutes of Health
Chair, Data and Safety Monitoring Committee, Sirolimus Treatment
of Geographic AMD, National Institutes of Health and Santen, Inc.
Chair, Data and Safety Monitoring Committee, Study of Comparative
Treatments for Retinal Vein Occlusion 2 (SCORE2), National Institutes
of Health
Data & Safety Monitoring Committee, META-MUST trials, National Institutes
of Health
Data & Safety Monitoring Board, Stopping Anti-TNF Agents in
Rheumatoid Arthritis (STARA), National Institutes of Health and
MedStar Health Research Institute
Christine C. Nelson, M.D.
Best Doctors in America
Co-Chair, Oculoplastics Curriculum Development Committee, International
Council of Ophthalmology
Howard R. Petty, Ph.D.
Special Emphasis Panel, Member Conflict: Biology, Pathophysiology
and Diseases of the Visual System (ZRG1BDCN-L 02M), National
Institutes of Health
Special Emphasis Panel, Ocular Diseases Pathophysiology and Therapeutic
Approaches (ZRG1BDCN-R 5M ),
National Institutes of Health
Grant Review Panel, France Ministry of Health
Julia E. Richards, Ph.D.
Editorial Board, G3: Genes, Genomes, Genetics
Scientific Advisory Board, The Glaucoma Foundation
Scientific Reviewer, International Retina Research Foundation
Dr. Douglas H. Johnson Award in National Glaucoma Research,
Bright Focus Foundation
Frank W. Rozsa, Ph.D.
Communicators Award, Association for Research in Vision and
Ophthalmology
Roni M. Shtein, M.D., M.S.
Best Doctors in America
Medical Advisory Board, Eye Bank Association of America
Medical Director, Eversight Michigan
Methodologist, Cornea & Anterior Segment Disorders Panel,
Ophthalmic Technology Assessment Committees, American Academy
of Ophthalmology
Methodologist, Refractive Management/Intervention Panel,
Terry J. Smith, M.D.
Best Doctors in America
Michael W. Smith-Wheelock, M.D.
Best Doctors in America
H. Kaz Soong, M.D.
Best Doctors in America
Medical Director, Eversight Michigan
Joshua D. Stein, M.D., M.S.
Best Doctors in America
Leadership Development Program XVIII, class of 2016, American
Academy of Ophthalmology Academy
Standing Committee on Eye Care and Ear, Nose, and Throat Conditions,
National Quality Forum
Shaffer Grants for Innovative Research, Glaucoma Research Foundation
22nd Annual Roger P. Mason, Sr., M.D. Lecture, Howard University,
Washington D.C.
32
FACULTY HONORS AND RECOGNITION
Alan Sugar, M.D.
JULY 1, 2014 — SEPTEMBER 30, 2015
UNIVERSITY OF MICHIGAN AWARDS
Best Doctors in America
Editor-in-Chief, Cornea, Journal of the Cornea Society
David A. Antonetti, Ph.D
Medical Director, Eversight Michigan
B-EYE Challenge Award, University of Michigan Biointerfaces Institute
Medical Advisory Board, Eye Bank Association of America
Research Committee, Eye Bank Association of America
Cagri G. Besirli, M.D., Ph.D.
Frank Polack, M.D., Memorial Lecture in Cornea, University of Florida
University of Michigan Coulter Translational Research Program Award
Debra A. Thompson, Ph.D.
for Life Sciences Program Kickstart Award
Editorial Board, Experimental Eye Research
University of Michigan Translational Research and Commercialization
Brenda L. Bohnsack, M.D., Ph.D.
Susan S. Thoms, M.D.
Helmut F. Stern Career Development Professor of Ophthalmology
Best Doctors in America
and Visual Sciences
Jonathan D. Trobe, M.D.
Hakan Demirci, M.D.
Best Doctors in America
B-EYE Challenge Award, University of Michigan Biointerfaces Institute
Castle Connolly Top Doctors
Arthur Wolintz Memorial Lecture, Department of Ophthalmology,
State University of New York (SUNY) Downstate Medical Center
Philip C. Hessburg Lecture, 2015 Annual Alumni Meeting, Department
of Ophthalmology, Henry Ford Hospital
A.E. Finley Distinguished Visiting Professor, Department of Ophthalmology,
University of North Carolina
Joshua P. Vrabec, M.D.
Best Doctors in America
Sara Weidmayer, O.D.
Admittance Committee, American Academy of Optometry
Jennifer S. Weizer, M.D.
Best Doctors in America
Kwoon Y. Wong, Ph.D.
Editorial Board, Current Eye Research
Grant Reviewer, Velux Foundations
Special Emphasis Panel, Molecular and Cellular Substrates of Complex
Brain Disorders [ZRG1 MDCN-P 57], National Institutes of Health
Special Emphasis Panel, Neurobiology of Visual Perception and Decision
Making [ZRG1 IFCN-Q 02]], National Institutes of Health
Maria A. Woodward, M.D.
Medical Director, Eversight Michigan
Achievement Award, American Academy of Ophthalmology
Dongli Yang, M.D., Ph.D.
Editorial Board, Austin Journal of Clinical Ophthalmology
David N. Zacks, M.D., Ph.D.
Best Doctors in America
Achievement Award, American Academy of Ophthalmology
Thomas W. Gardner, M.D., M.S.
Senior Scholar at the University of Michigan A. Alfred Taubman Medical
Research Institute
K. Thiran Jayasundera, M.D.
University of Michigan Translational Research and Commercialization
for Life Sciences Program Award
Shahzad I. Mian, M.D.
Gilbert Whitaker Fund for the Improvement of Teaching, University
of Michigan Center for Research on Learning and Teaching
Paula Anne Newman-Casey, M.D., M.S.
Community Service Award, University of Michigan Medical School
Howard R. Petty, Ph.D.
University of Michigan Translational Research and Commercialization
for Life Sciences Program Award
Rajesh C. Rao, M.D.
Leslie H. and Abigail S. Wexner Emerging Scholar at the University
of Michigan A. Alfred Taubman Medical Research Institute
University of Michigan Biointerfaces Institute Award
Joshua D. Stein, M.D., M.S. Edward T. and Ellen K. Dryer Career Development Professor in
Ophthalmology and Visual Sciences
Alan Sugar, M.D.
League of Clinical Excellence, University of Michigan Medical School
Maria A. Woodward, M.D.
Project Award, University of Michigan Health System Fostering
Innovations Grants (FIGS) Program
33
FACULTY PUBLICATIONS JULY 1, 2014 — SEPTEMBER 30, 2015
Airik R, Slaats GG, Guo Z, Weiss AC,
Bainbridge JW...Thompson DA...Ali RR, et al.
Boynton GE, Raoof D, Niziol LM, Hussain M,
Khan N, Ghosh A, Hurd TW, Bekker-Jensen S,
Long-term effect of gene therapy on Leber's
Mian SI. Prospective randomized trial compar-
Schroder JM, Elledge SJ, Andersen JS, Kispert
congenital amaurosis. N Engl J Med. 2015
ing efficacy of topical loteprednol etabonate
A, Castelli M, Boletta A, Giles RH, Hildebrandt
May;372(20):1887-97.
0.5% versus cyclosporine-a 0.05% for treat-
F. Renal-retinal ciliopathy gene Sdccag8 regu-
ment of dry eye syndrome following hemato-
lates DNA damage response signaling. J Am
Bansal S, Balakrishnan SA, Blachley T, Weizer
poietic stem cell transplantation. Cornea. 2015
Soc Nephrol. 2014 Nov;25(11):2573-83.
JS, Lee PP, Stein JD. Subsequent receipt of
Jul;34(7):725-32.
interventions for glaucoma among a nationAlapati AN, Goetz K, Suk J, Navani M,
wide sample of patients who underwent laser
Boynton GE, Stem MS, Kwark L, Jackson
Al-Tarouti A, Jayasundera KT, Lee P, Tumminia
peripheral iridotomy. Am J Ophthalmol. 2015
GR, Farsiu S, Gardner TW. Multimodal
SJ, Ayyagari R. Molecular diagnostic testing
Aug;160(2):275-82.
characterization of proliferative diabetic
by eyeGENE(R). Analysis of patients with he-
retinopathy reveals alterations in outer retinal
reditary retinal dystrophy phenotype involving
Bashshur RL, Shannon GW, Smith BR,
function and structure. Ophthalmology. 2015
central vision loss. Invest Ophthalmol Vis Sci.
Woodward MA. The empirical evidence
May;122(5):957-67.
2014 Jul;55(9):5510-21.
for the telemedicine intervention in diabetes
Apkarian AO, Hervey-Jumper SL, Trobe JD.
management. Telemed J E Health. 2015
Boynton GE, Woodward MA. Evolving tech-
May;21(5):321-54.
niques in corneal transplantation. Curr Surg
Cerebrospinal fluid leak presenting as oculor-
Rep. 2015 Feb;3(2).
rhea after blunt orbitocranial tauma. J Neur-
Bavinger JC, DeLoss K, Mian SI. Scleral lens
oophthalmol. 2014 Sep;34(3):271-3.
use in dry eye syndrome. Curr Opin Ophthal-
Boynton GE, Woodward MA. Eye-bank
mol. 2015 Jul;26(4):319-24.
preparation of endothelial tissue. Curr Opin
Argento A, Kim W, Rozsa FW, DeBolt KL,
Ophthalmol. 2014 Jul;25(4):319-24.
Zikanova S, Richards JR. Shear behavior of
Bennett JL, O'Connor KC, Bar-Or A, Zamvil
bovine scleral tissue. J Biomech Eng. 2014
SS, Hemmer B, Tedder TF, von Budingen HC,
Breker DA, Little AA, Trobe JD. Autoim-
Jul;136(7).
Stuve O, Yeaman MR, Smith TJ, Stadelmann
mune acquired rippling muscle disease and
C. B lymphocytes in neuromyelitis optica.
myasthenia gravis. J Neuroophthalmol. 2014
Arora KS, Robin AL, Corcoran KJ, Corcoran
Neurol Neuroimmunol Neuroinflamm. 2015
Mar;35(1):98-9.
SL, Ramulu PY. Use of various glaucoma surger-
May;2(3):e104.
ies and procedures in Medicare beneficiaries
Breker DA, Stacey AW, Srinivasan A, Bursztyn
from 1994 to 2012. Ophthalmology. 2015
Boss JD, Shah CT, Elner VM, Hassan AS.
LL, Trobe JD, Johnson MW. Vision loss caused
Aug;122(8):1615-24.
Assessment of office-based practice patterns on
by retinal and lateral geniculate nucleus infarc-
protective eyewear counseling for patients with
tion in H1N1 influenza. J Neuroophthalmol.
Atkins SJ, Lentz SI, Fernando R, Smith TJ.
monocular vision. Ophthal Plast Reconstr Surg.
2015 Sep;35(3):265-9.
Disrupted TSH receptor expression in female
2015 Sep-Oct;31(5):361-3.
mouse lung fibroblasts alters subcellular IGF-1
Briceño CA, Zhang-Nunes SX, Massry GG.
receptor distribution. Endocrinology. 2015
Boyer DS, Goldbaum M, Leys AM, Starita C,
Minimally invasive surgical adjuncts to upper
Sep 21. [Epub ahead of print]
Study Group: Johnson MW. Effect of pegap-
blepharoplasty. Facial Plast Surg Clin North
tanib sodium 0.3 mg intravitreal injections
Am. 2015 May;23(2):137-51.
Bailey JN...Lichter PR...Moroi SE, Richards
(Macugen) in intraocular pressure: posthoc
JE, et al. Hypothesis-independent pathway
analysis from V.I.S.I.O.N. study. Br J Ophthal-
Brown JC, Goldstein JE, Chan TL, Massof R,
analysis implicates GABA and Acetyl-CoA me-
mol. 2014 Nov;98(11):1543-6.
Ramulu P, Low Vision Research Network Study
tabolism in primary open-angle glaucoma and
Group: Day SH, Wicker DM. Characterizing
normal-pressure glaucoma. Hum Genet. 2014
functional complaints in patients seeking out-
Oct;133(10):1319-30.
patient low-vision services in the United States.
Ophthalmology. 2014 Aug;121(8):1655-62
e1651.
34
FACULTY PUBLICATIONS JULY 1, 2014 — SEPTEMBER 30, 2015
Chan TL, Perlmutter MS, Andrews M, Sun-
Coit P, De Lott LB, Nan B, Elner VM, Sawalha
de Melo Franco R, Kron-Gray MM, De la
ness JS, Goldstein JE, Massof RW, Low Vision
AH. DNA methylation analysis of the temporal
Parra-Colin P, He Y, Musch DC, Mian SI, Niziol
Research Network Study Group: Day SH,
artery microenvironment in giant cell arteritis.
L, Soong HK. Outcomes of cataract surgery
Wicker DM. Equating visual function scales
Ann Rheum Dis. 2015 Jun 2. [Epub ahead
in graft-versus-host disease. Cornea. 2015
to facilitate reporting of medicare functional
of print]
May;34(5):506-11.
vision patients. Arch Phys Med Rehabil. 2015
Cornblath WT. Diplopia due to ocular motor
Demirci H, Cullen A, Sundstrom JM.
Jul 9. [Epub ahead of print]
cranial neuropathies. Continuum (Minneap
Enhanced depth imaging optical coherence
Minn). 2014 Aug;20(4):966-80.
tomography of choroidal metastasis. Retina.
g-code severity/complexity modifiers for low-
Chaudhary N, Griauzde J, Gemmete JJ,
2014 Jul;34(7):1354-9.
Pandey AS, Trobe JD. Issues in the diagnosis
Daniel E, Quinn GE, Hildebrand PL, Ells A,
and management of the papilledema shunt.
Hubbard GB, 3rd, Capone A, Jr., Martin ER,
Demirci H, Elner VM. Contemplating the
J Neuroophthalmol. 2014 Sep;34(3):259-63.
Ostroff CP, Smith E, Pistilli M, Ying GS,
diagnostic certainty of primary iris mucosa-
e-ROP Cooperative Group: Musch DC.
associated lymphoid tissue Lymphoma-Reply.
Chen H, Mester T, Raychaudhuri N, Kauh
Validated system for centralized grading of
JAMA Ophthalmol. 2015 Aug 1. [Epub ahead
CY, Gupta S, Smith TJ, Douglas RS. Tepro-
retinopathy of prematurity: telemedicine ap-
of print]
tumumab, an IGF-1R blocking monoclonal
proaches to evaluating acute-phase retinopathy
antibody inhibits TSH and IGF-1 action in
of prematurity (e-ROP) study. JAMA Ophthal-
Demirci H, Grant JS, Elner VM. Intralesional
fibrocytes. J Clin Endocrinol Metab. 2014
mol. Jun 2015;133(6):675-82.
rituximab for primary iris lymphoma. JAMA
Sep;99(9):E1635-40.
Ophthalmol. 2015 Jan;133(1):104-5.
Davis RL, Eiden SB, Bennett ES, Koffler B,
Chen H, Shan SJ, Mester T, Wei YH, Douglas
Wohl L, Lipson M. Stabilizing myopia by
Demirci H, Saponara F, Khan A, Niziol LM,
RS. TSH-mediated TNFalpha production in
accelerating reshaping technique (SMART)-
Lee C, Hayman JA, Comer G, Musch DC.
human fibrocytes is inhibited by teprotumumab,
study three year outcomes and overview. Adv
Regression rate of posterior uveal melanomas
an IGF-1R antagonist. PLoS One. 2015
Ophthalmol Vis Syst. 2015 Apr;2(3):00046.
following iodine-125 plaque radiotherapy.
June;10(6):e0130322.
Middle East Afr J Ophthalmol. 2015 JanDe la Parra-Colin PD, Barrientos-Gutierrez T,
Mar;22(1):103-7.
Chou CM, Nelson C, Tarlé SA, Pribila JT,
Mian SI. Axial length's role in intraocular lens
Bardakjian T, Woods S, Schneider A, Glaser
power calculation error in x-linked megalocor-
Demirci H, Steen DW. Limitations in imaging
T. Biochemical basis for dominant inheritance,
nea: a case-series analysis. Ophthalmic Genet.
common conjunctival and corneal pathologies
variable penetrance, and maternal effects in
2014;35(3):180-3.
with fourier-domain optical coherence tomog-
RBP4 congenital eye disease. Cell. 2015
Apr 23;161(3):634-46.
raphy. Middle East Afr J Ophthalmol. 2014
DeLoss KS, Fatteh NH, Hood CT. Prosthetic
Jul-Sep;21(3):220-4.
replacement of the ocular surface ecosystem
Choudhry N, Rao RC. Enhanced depth imag-
(PROSE) scleral device compared to kerato-
Demirci H, Worden F, Nelson CC, Elner VM,
ing features of a choroidal macrovessel. Retin
plasty for the treatment of corneal ectasia.
Kahana A. Efficacy of vismodegib (erivedge)
Cases Brief Rep. 2015 May 29. [Epub ahead
Am J Ophthalmol. 2014 Nov;158(5):974-82.
for basal cell carcinoma involving the orbit and
of print]
periocular area. Ophthal Plast Reconstr Surg.
De Lott LB, Burke JF; Michigan Neuro-Ophthal-
2015 Feb 11. [Epub ahead of print]
Choudhry N, Rao RC. Multimodal ultrawide-
mology Research Consortium. Use of labora-
field imaging features in Waardenburg
tory markers in deciding whether to perform
Dennis MD, Kimball SR, Fort PE, Jefferson LS.
syndrome. Ophthalmic Surg Lasers Imaging
temporal artery biopsy. JAMA Ophthalmol.
Regulated in development and DNA damage
Retina. 2015 Jun;46(6):670-3.
2015 May;133(5):605-6.
1 is necessary for hyperglycemia-induced
vascular endothelial growth factor expression
in the retina of diabetic rodents. J Biol Chem.
2015 Feb 6;290(6):3865-74.
35
FACULTY PUBLICATIONS JULY 1, 2014 — SEPTEMBER 30, 2015
Dlouhy BJ, Awe O, Rao RC, Kirby PA, Hitchon
Fernando R, Lu Y, Atkins SJ, Mester T,
Garnai SJ, Huyghe JR, Reed DM, Scott KM,
PW. Autograft-derived spinal cord mass follow-
Branham K, Smith TJ. Expression of thyro-
Liebmann JM, Boehnke M, Richards JE, Ritch
ing olfactory mucosal cell transplantation in a
tropin receptor, thyroglobulin, sodium-iodide
R, Pawar H. Congenital cataracts: de novo
spinal cord injury patient. J Neurosurg Spine.
symporter, and thyroperoxidase by fibrocytes
gene conversion event in CRYBB2. Molecular
2014 Oct;21(4):618-22.
depends on AIRE. J Clin Endocrinol Metab.
Vision. 2014 Nov;20:1579-93.
2014 Jul;99(7):E1236-44.
Du Y, Cramer M, Lee CA, Tang J, Muthusamy
A, Antonetti DA, Jin H, Palczewski K, Kern
Ghodasra DH, Demirci H. Photodynamic
Fort PE, Darche M, Sahel JA, Rendon A,
therapy for choroidal metastasis. Am Ophthal-
TS. Adrenergic and serotonin receptors affect
Tadayoni R. Lack of dystrophin protein Dp71
mol. 2015 Sep 30. [Epub ahead of print]
retinal superoxide generation in diabetic mice:
results in progressive cataract formation due
relationship to capillary degeneration and
to loss of fiber cell organization. Molecular
Goldstein JE, Jackson ML, Fox SM, Deremeik
permeability. FASEB J. 2015 May;29(5):
Vision. 2014 Nov;20:1480-90.
JT, Massof RW, Low Vision Research Network
2194-204.
Study Group: Day SH, Wicker DM. Clinically
Fort PE, Losiewicz MK, Pennathur S, Jefferson
meaningful rehabilitation outcomes of low vi-
Dulle JE, Fort PE. Crystallins and neuroinflam-
LS, Kimball SR, Abcouwer SF, Gardner TW.
sion patients served by outpatient clinical cen-
mation: the glial side of the story. Biochim Bio-
mTORC1-independent reduction of retinal
ters. JAMA Ophthalmol. 2015;133(7):762-9.
phys Acta. 2015 Jun 3. [Epub ahead of print]
protein synthesis in type 1 diabetes. Diabetes.
2014 Sep;63(9):3077-90.
Gramage E, D'Cruz T, Taylor S, Thummel R,
Syed R, Soudry S, Menghini M, Caruso RC,
French CR, Seshadri S, Destefano AL, Fornage
the developing and adult retina of the zebrafish
Jeffrey BG, Heckenlively JR, Reddy GB, Lee P,
M, Arnold CR, Gage PJ, Skarie JM, Dobyns
and its function during photoreceptor regenera-
Roorda A, Ayyagari R. Ocular phenotype of a
WB, Millen KJ, Liu T, Dietz W, Kume T, Hofker
tion. PLoS One. 2015 Mar;10(3):e0121789.
family with FAM161A-associated retinal degen-
M, Emery DJ, Childs SJ, Waskiewicz AJ,
eration. Ophthalmic Genet. 2014:1-9.
Lehmann OJ. Mutation of FOXC1 and PITX2
Grzegorski SJ, Chiari EF, Robbins A, Kish PE,
induces cerebral small-vessel disease. J Clin
Kahana A. Natural variability of Kozak se-
Invest. 2014 Nov;124(11):4877-81.
quences correlates with function in a zebrafish
Duncan JL, Biswas P, Kozak I, Navani M,
Dunn SP, Gal RL, Kollman C, Raghinaru D,
Hitchcock PF. Midkine-a protein localization in
Dontchev M, Blanton CL, Holland EJ, Lass JH,
model. PLoS One. 2014 Sep;9(9):e108475.
Kenyon KR, Mannis MJ, Mian SI, Rapuano
Gage PJ, Kuang C, Zacharias AL. The home-
CJ, Stark WJ, Beck RW. Corneal graft rejec-
odomain transcription factor PITX2 is required
Gulati S, Andrews CA, Apkarian AO, Musch
tion 10 years after penetrating keratoplasty
for specifying correct cell fates and establishing
DC, Lee PP, Stein JD. Effect of gestational
in the Cornea Donor Study. Cornea. 2014
angiogenic privilege in the developing cornea.
age and birth weight on the risk of strabismus
Oct;33(10):1003-9.
Dev Dyn. 2014 Nov;243(11):1391-400.
among premature infants. JAMA Pediatr. 2014
Eisma JH, Dulle JE, Fort PE. Current knowledge
Galvin JA, LeBoyer RM, Michelotti M,
on diabetic retinopathy from human donor
Del Monte MA, Elner VM, Mian SI. Mosaic
Gupta C, Tanaka TS, Elner VM, Soong HK.
tissues. World J Diabetes. 2015 Mar;6(2):
chromosome 18q partial deletion syndrome
Acute hydrops with corneal perforation in
312-20.
with bilateral full-thickness corneal disease:
post-LASIK ectasia. Cornea. 2015 Jan;34(1):
surgical intervention and histopathology.
99-100.
Sep;168(9):850-6.
Elam AR, Lee PP. Barriers to and suggestions
Ophthal Genetics. 2015 Mar;36(1):75-8.
on improving utilization of eye care in high-risk
Haller T, Furr BA. Fresnel prism use among
individuals: focus group results. Int Sch Res
Gardner TW, Abcouwer SF, Losiewicz MK,
Notices. 2014 Oct, Article ID 527831.
Fort PE. Phosphatase control of 4E-BP1 phosphorylation state is central for glycolytic regulation of retinal protein synthesis. Am J Physiol
Endocrinol Metab. 2015 Sep 15;309(6):
E546-56.
36
orthoptists. Am Orthopt J. 2014;64(1):71-5.
FACULTY PUBLICATIONS JULY 1, 2014 — SEPTEMBER 30, 2015
He Y, de Melo Franco R, Kron-Gray MM,
Jain N, Kozak JA, Niziol LM, Musch DC,
Kim DS, Korgavkar K, Zahid S, De Lott L,
Musch DC, Soong HK. Outcomes of cataract
Zacks DN. Vitrectomy alone in the man-
Prabhakar A, Foerster BR, Besirli CG. Vision
surgery in eyes with previous herpes zoster
agement of giant retinal tears. Ophthalmic
loss after central retinal artery occlusion sec-
ophthalmicus. J Cataract Refract Surg. 2015
Surg Lasers Imaging Retina. 2014 Sep-
ondary to orbital sarcoid mass. Ophthal Plast
Apr;41(4):771-7.
Oct;45(5):421-7.
Reconstr Surg. 2014 Jul 28. [Epub ahead of
Helm JE, Lavieri MS, Van Oyen MP, Stein JD,
Jayakody SA, Gonzalez-Cordero A, Ali RR,
Musch DC. Dynamic forecasting and control al-
Pearson RA. Cellular strategies for retinal
Kirtland KA, Saaddine JB, Geiss LS, Thompson
gorithms of glaucoma progression for clinician
repair by photoreceptor replacement. Prog
TJ, Cotch MF, Lee PP. Geographic disparity
decision support. Operations Research. 2015
Retin Eye Res. 2015 May;46:31-66.
of severe vision loss - United States, 2009-
print]
Sep 9. [Epub ahead of print]
2013. MMWR Morb Mortal Wkly Rep. 2015
Johnson MW, Fahim AT, Rao RC. Acute
Hood CT, Bernard H. Conjunctival pigmenta-
ocriplasmin retinopathy. Retina. 2015
tion associated with long-term minocycline
Jun;35(6):1055-8.
therapy. EyeNet. August 2014;18(8):2.
May;64(19):513-7.
Komaromy AM, Abrams KL, Heckenlively JR,
Lundy SK, Maggs DJ, Leeth CM, MohanKumar
Katz DM, Trobe JD. Is there treatment for
PS, Petersen-Jones SM, Serreze DV, van der
Hood CT, Sugar A. Subjective complaints after
nonarteritic anterior ischemic optic neuropathy.
Woerdt A. Sudden acquired retinal degenera-
cataract surgery: common causes and manage-
Curr Opin Ophthalmol. 2015 Sep 11. [Epub
tion syndrome (SARDS) - a review and pro-
ment strategies. Curr Opin Ophthalmol. 2015
ahead of print]
posed strategies toward a better understanding
Jan;26(1):45-9.
of pathogenesis, early diagnosis, and therapy.
Kauh CY, Gupta S, Douglas RS, Elner VM,
Vet Ophthalmol. 2015 Jun 20. [Epub ahead
Huang JT, Heckenlively JR, Jayasundera KT,
Nelson CC, Niziol LM, Kahana A. Compres-
of print]
Branham KE. The ophthalmic experience: un-
sive optic neuropathy and repeat orbital
anticipated primary findings in the era of next
decompression: a case series. Ophthal Plast
Kommaraju KR, Moroi S, Demirci H. Diffuse
generation sequencing. J Genet Couns. 2014
Reconstr Surg. 2015 Sep-Oct;31(5):385-90.
anterior scleritis and secondary glaucoma as
Aug;23(4):588-93.
a manifestation of adult T-cell prolymphocytic
Khan M, Rao PK, Rao RC. Shimmering lights.
Hussain M, Shtein RM, Sugar A, Soong HK,
leukemia. Cornea. 2014 Aug;33(8):873-4.
JAMA Ophthalmol. 2014 Aug;132(8):1015-6.
Woodward MA, DeLoss K, Mian SI. Long-term
Kremer S...Smith TJ, et al. Use of advanced
use of autologous serum 50% eye drops for the
Khan M, Walters LL, Li Q, Thomas DG, Miller
magnetic resonance imaging techniques in
treatment of dry eye disease. Cornea. 2014
JM, Zhang Q, Sciallis AP, Liu Y, Dlouhy BJ, Fort
neuromyelitis optica spectrum disorder. JAMA
December;33(12):1245-51.
PE, Archer SM, Demirci H, Dou Y, Rao RC.
Neurol. 2015 Jul;72(7):815-22.
Characterization and pharmacologic targeting
Hysi PG...Moroi SE, et al. Genome-wide
of EZH2, a fetal retinal protein and epigenetic
Kristensen B, Hegedus L, Lundy SK, Brimnes
analysis of multi-ancestry cohorts identifies
regulator, in human retinoblastoma. Lab Invest.
MK, Smith TJ, Nielsen CH. Characteriza-
new loci influencing intraocular pressure and
2015 Aug 17. [Epub ahead of print]
tion of regulatory B cells in Graves' disease
susceptibility to glaucoma. Nat Genet. 2014
Oct;46(10):1126-30.
and Hashimoto's thyroiditis. PLoS One. 2015
Khatib N, Polk T, Johnson MW. Diagnostic
May;10(5):e0127949.
and therapeutic challenges. Retina. 2015
Jackson GR, Gardner TW. Visual fields refine
Jan;35(1):157-60.
understanding of diabetic retinopathy progression. Diabetes. 2014 Sep;63(9):2909-10.
Jain N, Johnson MW. Pathogenesis and treatment of maculopathy associated with cavitary
Kristensen B, Hegedus L, Madsen HO,
Smith TJ, Nielsen CH. Altered balance be-
Kiang L, Kahana A. Images in clinical
tween self-reactive Th17 cells and Th10 cells
medicine. Orbital varix. N Engl J Med. 2015
and between full-length FOXP3 and FOXP3
Feb;372(7):e9.
splice variants in Hashimoto's thyroiditis.
Clin Exp Immunol. 2015 Apr;180(1):58-69.
optic disc anomalies. Am J Ophthalmol. 2014
Sep;158(3):423-35.
37
FACULTY PUBLICATIONS JULY 1, 2014 — SEPTEMBER 30, 2015
Lagina A. Don't forget contact lenses in ocular
Lichter PR. Payment data and the "me"
Marshall J, Wong KY, Rupasinghe CN, Tiwari
rosacea. Rev Optom. 2015 Apr;152(4):50.
in Medicare. Ophthalmology. 2014
R, Zhao X, Berberoglu ED, Sinkler C, Liu J, Lee
Oct;121(10):1849-51.
I, Parang K, Spaller MR, Huttemann M, Goebel
Lagina AL. Soft contact lens optimizes visual
DJ. Inhibition of n-methyl-d-aspartate-induced
goals for a patient with keratoectasia. Optom
Lin HC, Stein JD, Nan B, Childers D,
retinal neuronal death by polyarginine pep-
Vis Sci. 2015 Sep 18. [Epub ahead or print]
Newman-Casey PA, Thompson DA, Richards
tides is linked to the attenuation of stress-in-
JE. Association of geroprotective effects of
duced hyperpolarization of the inner mitochon-
Lass JH, Riddlesworth TD, Gal RL, Kollman
metformin and risk of open-angle glaucoma in
drial membrane potential. J Biol Chem. 2015
C, Benetz BA, Price FW Jr, Sugar A, Terry
persons with diabetes mellitus. JAMA Ophthal-
Sep 4;290(36):22030-48.
MA, Soper M, Beck RW. Cornea Donor Study
mol. 2015 Aug 1;133(8):915-23.
Research Group. The effect of donor diabetes
McCartney AJ, Zolov SN, Kauffman EJ,
history on graft failure and endothelial cell
Lipson MJ. Axial length measurement:
Zhang Y, Strunk BS, Weisman LS, Sutton MA.
density 10 years after penetrating keratoplasty.
PalmScan versus IOLMaster. Eye Contact Lens.
Activity-dependent PI(3,5)P2 synthesis controls
Ophthalmology. 2015 Mar;122(3):448-56.
2015 May;41(3):156-9.
AMPA receptor trafficking during synaptic
Lee BJ, Atkins S, Ginter A, Elner VM, Nelson
Liu H, Tang J, Du Y, Lee CA, Golczak M,
CC, Douglas RS. Increased CD40+ fibrocytes
Muthusamy A, Antonetti DA, Veenstra AA,
in patients with idiopathic orbital inflammation.
Amengual J, Von Lintig J, Palczewski K,
McCoy AN, Kim DS, Gillespie E, Atkins S,
Ophthal Plast Reconstr Surg. 2015 May-
Kern TS. Retinylamine benefits early dia-
Smith TJ, Douglas RS. Rituximab (Rituxan(R))
Jun;31(3):202-6.
betic retinopathy in mice. J Biol Chem. 2015
therapy for severe thyroid associated oph-
Aug;290(35):21568-79.
thalmopathy diminishes IGF-1R T cells. J Clin
depression. Proc Natl Acad Sci USA. 2014
Lee WB, Shtein RM, Kaufman SC, Deng SX,
Nov;111(45):E4896-905.
Endocrinol Metab. 2014 Jul;99(7):E1294-9.
Rosenblatt MI. Boston keratoprosthesis:
Liu Y...Lichter PR, Moroi SE...Richards J, et al.
outcomes and complications: a report by
DNA copy number variants of known glau-
Melamed E...Smith TJ, et al. Update on bio-
the American Academy of Ophthalmology.
coma genes in relation to primary open-angle
markers in neuromyelitis optica. Neurol Neuro-
Ophthalmology. 2015 Jul;122(7):1504-11.
glaucoma. Invest Ophthalmol Vis Sci. 2014
immunol Neuroinflamm. Aug 2015;2(4):e134.
Nov;55(12):8251-8.
Lertakyamanee P, Srinivasan A, De Lott LB,
Mian SI. Evaporative dry eye disease: promis-
Trobe JD. Papilledema and vision loss caused
Majmudar PA, Schallhorn SC, Cason JB,
ing new approaches for diagnosis and treat-
by jugular paragangliomas. J Neuroophthal-
Donaldson KE, Kymionis GD, Shtein RM, Verity
ment [Editorial]. Curr Opin Ophthalmol. 2015
mol. 2015 Jun 12. [Epub ahead of print]
SM, Farjo AA. Mitomycin-C in corneal surface
Jul;26(4):288.
excimer laser ablation techniques: a report
Li B, Smith TJ. PI3K/AKT pathway mediates
by the American Academy of Ophthalmology.
Mian SI. Evolution of a revolution in
induction of IL-1RA by TSH in fibrocytes: modu-
Ophthalmology. 2015 Jun;122(6):1085-95.
keratoplasty. Curr Opin Ophthalmol. 2014
lation by PTEN. J Clin Endocrinol Metab. 2014
Sept;99(9):3363-72.
Jul;25(4):298-9.
Malta JB, Renesto AC, Moscovici BK, Soong
HK, Campos M. Stromal demarcation line
Michelotti MM, Gupta C, Hood CT. Persis-
Li Z... Richards JE, et al. A common variant
induced by corneal cross-linking in eyes with
tent amine keratopathy secondary to indirect
near TGFBR3 is associated with primary open
keratoconus and nonkeratoconic asymmetric to-
exposure to spray polyurethane foam insulation
angle glaucoma. Hum Mol Genet. 2015
pography. Cornea. 2015 Feb;34(2):199-203.
[Ophthalmic Image]. JAMA Ophthalmol. 2015
Jul;24(13):3880-92.
Jun;133(6):e1584.
Marcet MM, Shtein RM, Bradley EA, Deng SX,
Lichter PR. Implications of the sunshine act-
Meyer DR, Bilyk JR, Yen MT, Lee WB, Mawn
Michelotti MM, Jain N, Johnson MW. Bilateral
revelations, loopholes, and impact. Ophthal-
LA. Safety and efficacy of lacrimal drainage
exudative retinal detachment in a diabetic
mology. 2015 Apr;122(4):653-5.
system plugs for dry eye syndrome: a report
patient with severe peripheral retinal ischemia.
by the American Academy Of Ophthalmology.
JAMA Ophthalmol. 2015 Jan;133(1):107-9.
Ophthalmology. 2015 Aug;122(8):1681-7.
38
FACULTY PUBLICATIONS JULY 1, 2014 — SEPTEMBER 30, 2015
Musch DC, Gillespie BW, Palmberg PF, Spaeth
Nika M, Blachley TS, Edwards P, Lee PP,
Peeler CE, De Lott LB, Nagia L, Lemos J,
G, Niziol LM, Lichter PR. Visual field improve-
Stein JD. Regular examinations for toxic macu-
Eggenberger ER, Cornblath WT. Clinical utility
ment in the collaborative initial glaucoma
lopathy in long-term chloroquine or hydroxy-
of acetylcholine receptor antibody testing in
treatment study. Am J Ophthalmol. 2014
chloroquine users. JAMA Ophthalmol. 2014
ocular myasthenia gravis. JAMA Neurol. 2015
Jul;158(1):96-104.
Oct;132(10):1199-208.
Aug 10. [Epub ahead of print]
Nagia L, Lemos J, Abusamra K, Cornblath WT,
Nika M, Kalyani PS, Jayasundera KT,
Ple-Plakon PA, Shtein RM. Trends in corneal
Eggenberger ER. Prognosis of ocular myasthe-
Comer GM. Pathogenesis of persistent placoid
transplantation: indications and techniques.
nia gravis: retrospective multicenter analysis.
maculopathy: a multimodal imaging analysis.
Curr Opin Ophthalmol. 2014 Jul;25(4):300-5.
Ophthalmology. 2015 Jul;122(7):1517-21.
Retina. 2015 Aug;35(8):1531-9.
Newman-Casey PA, Blachley T, Lee PP,
Novack GD, Robin AL. Ocular pharmacology.
Cooney TM. Topical cyclosporine A 0.05%
Heisler M, Farris KB, Stein JD. Patterns of
J Clin Pharmacol. Sep 2015. [Epub ahead
for recurrent anterior uveitis. Br J Ophthalmol.
glaucoma medication adherence over four
of print]
2015 Aug 18. [Epub ahead of print]
Ober MD, Freund KB, Shah M, Ahmed S,
Rajaii F, McCoy AN, Smith TJ. Cytokines are
Prabhu SS, Shtein RM, Michelotti MM,
years of follow-up. Ophthalmology. 2015
Oct;122(10):2010-21.
Mahmoud TH, Aaberg TM, Jr., Zacks DN,
both villains and potential therapeutic targets
Newman-Casey PA, Robin AL, Blachley T,
Gao H, Mukkamala K, Desai U, Packo KH,
in thyroid-associated ophthalmopathy: from
Farris K, Heisler M, Resnicow K, Lee PP. The
Yannuzzi LA. Stellate nonhereditary idiopathic
bench to bedside. Expert Rev Ophthalmol.
most common barriers to glaucoma medication
foveomacular retinoschisis. Ophthalmology.
2014 Jun;9(3):227-34.
adherence: a cross-sectional survey. Ophthal-
2014 Jul;121(7):1406-13.
mology. 2015 July;122(7):1308-16.
Rao P, Shah AR, Michelotti MM, AnderOliver V, Jaffe AE, Song J, Wang G, Zhang
son B, Abbey AM, Jain N, Stec L, Lowe L,
Newman-Casey PA, Shtein RM, Coleman AL,
P, Branham KE, Swaroop A, Eberhart CG,
Johnson MW, Williams GA. Bilateral acute
Herndon L, Lee PP. Why patients with glau-
Zack DJ, Qian J, Merbs SL. Differential
endophthalmitis associated with munchau-
coma lose vision: the patient perspective.
DNA methylation identified in the blood and
sen syndrome. Retin Cases Brief Rep. 2015
J Glaucoma. 2015 Aug 27. [Epub ahead
retina of AMD patients. Epigenetics. 2015
Spring;9(2):177-80.
of print]
Aug;10(8):698-707.
Newman-Casey PA, Stem M, Talwar N,
Pack W, Hill DD, Wong KY. Melatonin modu-
mia and unilateral eyelash hypertrichosis.
Musch DC, Besirli CG, Stein JD. Risk factors
lates M4-type ganglion-cell photoreceptors.
JAMA. 2015 May;313(19):1967-8.
associated with developing branch retinal vein
Neuroscience. 2015 Sep;303:178-88.
Rao RC, Ballard TN, Chen TC. Iris heterochro-
occlusion among enrollees in a United States
Rao RC, Choudhry N. Cystoid macular edema
managed care plan. Ophthalmology. 2014
Padhi TR, Besirli CG. Re: Lepore et al.: Intra-
associated with chemotherapy. CMAJ. 2015
Oct;121(10):1939-48.
vitreal bevacizumab versus laser treatment
Aug 4. [Epub ahead of print]
in type 1 retinopathy of prematurity: report
Newman-Casey PA, Verkade AJ, Oren GA,
on fluorescein angiographic findings (Letter).
Rao RC, Choudhry N. Enhanced depth imag-
Robin AL. Gaps in glaucoma care: a systemat-
Ophthalmology. 2015;122(8):e47-48.
ing spectral-domain optical coherence tomog-
ic review of monoscopic disc photos to screen
raphy findings in choroidal neurofibromatosis.
for glaucoma. Exp Rev Ophthalmol. 2014
Patane PS, Krummenacher TK, Rao RC. Val-
Ophthalmic Surg Lasers Imaging Retina. 2014
Dec;9(6):467-74.
salva hemorrhagic retinopathy presenting as a
Sept-Oct;45(5):466-8.
rare cause of impaired vision after a general
anesthetic-a case report and review of the literature. J Clin Anesth. 2015 Jun;27(4):341-6.
39
FACULTY PUBLICATIONS JULY 1, 2014 — SEPTEMBER 30, 2015
Rao RC, Cohen SR, Mian SI. Silicone oil
Saera-Vila A, Kasprick DS, Junttila TL,
Scott IU, Jackson GR, Quillen DA, Klein R,
retention sutures for retinal detachment repair
Grzegorski SJ, Louie KW, Chiari EF, Kish PE,
Liao J, Gardner TW. Effect of doxycycline
following traumatic aniridia, aphakia, and
Kahana A. Myocyte dedifferentiation drives
vs placebo on retinal function and diabetic
ruptured globe. JAMA Ophthalmol. Sep 10
extraocular muscle regeneration in adult
retinopathy progression in mild to moderate
2015;133(9):e151433.
zebrafish. Invest Ophthalmol Vis Sci. Jul 1
nonproliferative diabetic retinopathy: a ran-
2015;56(8):4977-93.
Rao RC, Dou Y. Hijacked in cancer: the KMT2
domized proof-of-concept clinical trial. JAMA
Ophthalmol. 2014 Sep;132(9):1137-42.
(MLL) family of methyltransferases. Nat Rev
Saera-Vila A, Kish PE, Kahana A. Automated
Cancer. 2015 Jun;15(6):334-46.
scalable heat shock modification for standard
Sealy-Jefferson S, Vickers J, Elam A, Wilson
aquatic housing systems. Zebrafish. 2015
MR. Racial and ethnic health disparities
Aug;12(4):312-4.
and the affordable care act: a status update.
Rao RC, Elner VM, Demirci H. A red and
swollen eyelid. Breast carcinoma metastasis
J Racial Ethn Health Disparities. 2015 Jul.
to left lacrimal gland. JAMA Oncol. 2015
Sand D, Amin S, Sugar A. April consulta-
Jul;1(4):537-8.
tion #2. J Cataract Refract Surg. 2015
Apr;41(4):896.
Rao RC, Khan M, Badiyan SN, Harbour JW.
[Epub ahead of print].
Shelby SJ, Angadi PS, Zheng QD, Yao J,
Jia L, Zacks DN. Hypoxia inducible factor
Gene expression profiling and regression
Savatovsky E, Mwanza JC, Budenz DL,
1alpha contributes to regulation of autophagy
rate of irradiated uveal melanomas. Oph-
Feuer WJ, Vandenbroucke R, Schiffman JC,
in retinal detachment. Exp Eye Res. 2015
thalmic Surg Lasers Imaging Retina. 2015
Anderson DR, Study Group: Bergstrom TJ,
Aug;137:84-93.
Mar;46(3):333-7.
Moroi SE, Pollack-Rundle CJ, Tehranisa MA.
Longitudinal changes in peripapillary atrophy
Shelby SJ, Feathers KL, Ganios AM, Jia L,
Ratnapriya R, Zhan X, Fariss RN,
in the ocular hypertension treatment study: a
Miller JM, Thompson DA. MERTK signaling
Branham KE...Heckenlively JR, et al. Rare
case-control assessment. Ophthalmology. 2015
in the retinal pigment epithelium regulates the
and common variants in extracellular matrix
Jan;122(1):79-86.
tyrosine phosphorylation of GDP dissociation
gene Fibrillin 2 (FBN2) are associated with
inhibitor alpha from the GDI/CHM family of
macular degeneration. Hum Mol Genet. 2014
Sayner R, Carpenter DM, Blalock SJ, Robin
RAB GTPase effectors. Exp Eye Res. 2015 Aug
Nov;23(21):5827-37.
AL, Muir KW, Hartnett ME, Giangiacomo AL,
15;140:28-40.
Tudor G, Sleath B. Accuracy of patient-reportReifler AN, Chervenak AP, Dolikian ME,
ed adherence to glaucoma medications on a
Singh RK, Mallela RK, Cornuet PK, Reifler AN,
Benenati BA, Meyers BS, Demertzis ZD, Lynch
visual analog scale compared with electronic
Chervenak AP, West MD, Wong KY, Nasonkin
AM, Li BY, Wachter RD, Abufarha FS, Dulka
monitors. Clin Ther. 2015 Sep 1;37(9):1975-
IO. Characterization of three-dimensional reti-
EA, Pack W, Zhao X, Wong KY. The rat retina
85.
nal tissue derived from human embryonic stem
has five types of ganglion-cell photoreceptors.
Exp Eye Res. 2015 Jan;130:17-28.
cells in adherent monolayer cultures. Stem Cells
Schell GJ, Lavieri MS, Helm JE, Liu X, Musch
Dev. 2015 Sep 10. [Epub ahead of print]
DC, Van Oyen MP, Stein JD. Using filtered
Rootman DB, Kim MJ, Aldave AJ, Douglas R,
forecasting techniques to determine personal-
Sleath B, Blalock SJ, Carpenter DM, Sayner R,
Hwang C, Goldberg R. Ocular surface, fornix,
ized monitoring schedules for patients with
Muir KW, Slota C, Lawrence SD, Giangiacomo
and eyelid rehabilitation in Boston type I kera-
open-angle glaucoma. Ophthalmology. 2014
AL, Hartnett ME, Tudor G, Goldsmith JA,
toprosthesis patients with mucous membrane
Aug;121(8):1539-46.
Robin AL. Ophthalmologist-patient com-
disease. Ophthal Plast Reconstr Surg. 2015
Jan-Feb;31(1):43-9.
munication, self-efficacy, and glaucoma
Scherer LD, Finan C, Simancek D, Finkelstein
medication adherence. Ophthalmology. 2014
JI, Tarini BA. Effect of "pink eye" label on
Apr;122(4):748-54.
parents' intent to use antibiotics and perceived
contagiousness. Clin Pediatr (Phila). 2015 Aug
20. [Epub ahead of print]
40
FACULTY PUBLICATIONS JULY 1, 2014 — SEPTEMBER 30, 2015
Sleath B, Carpenter DM, Blalock SJ, Sayner R,
Stein JD, Childers D, Gupta S, Talwar N, Nan
Sugar A, Gal RL, Kollman C, Raghinaru
Muir KW, Slota C, Giangiacomo AL, Hartnett
B, Lee BJ, Smith TJ, Douglas R. Risk factors for
D, Dontchev M, Croasdale CR, Feder RS,
ME, Tudor G, Robin AL. Applying the resourc-
developing thyroid-associated ophthalmopathy
Holland EJ, Lass JH, Macy JI, Mannis MJ,
es and supports in self-management framework
among individuals with Graves disease. JAMA
Smith PW, Soukiasian SH, Beck RW. Factors
to examine ophthalmologist-patient communi-
Ophthalmol. 2015 Mar;133(3):290-6.
associated with corneal graft survival in the
cation and glaucoma medication adherence.
Health Educ Res. Oct 2015;30(5):693-705.
cornea donor study. JAMA Ophthalmol. 2015
Stein JD, Shekhawat N, Talwar N, Balkrishnan
Mar;133(3):246-54.
R. Impact of the introduction of generic LatanoSlota C, Sayner R, Vitko M, Carpenter DM,
prost on glaucoma mediation adherence.
Sugar A, Sugar J, Schwab I, Perry H, de Luise
Blalock SJ, Robin AL, Muir KW, Hartnett ME,
Ophthalmology. 2015 Apr;122(4):738-47.
V, Soong HK, Weiss J. Do it right the first time:
Sleath B. Glaucoma patient expression of medi-
advice for cornea authors. Cornea. 2014
cation problems and nonadherence. Optom
Stein JD, Talwar N, Kang JH, Okereke OI,
Vis Sci. 2015 Oct;92(5):537-43.
Wiggs JL, Pasquale LR. Bupropion use and risk
Sep;33(9):879.
of open-angle glaucoma among enrollees in a
Suner IJ, Margolis J, Ruiz K, Tran I, Lee P.
Smith TA, Cornblath WT. Alternating superior
large U.S. managed care network. PLoS One.
Direct medical costs and resource use for
and inferior oblique myokymia. JAMA Ophthal-
2015 Apr;10(4):e0123682.
treating central and branch retinal vein oc-
mol. 2014 Jul;132(7):898-9.
clusion in commercially insured working-age
Stem MS, Fahim A, Trobe JD, Parmar HA,
and Medicare populations. Retina. 2014
Smith TJ. TSH-receptor-expressing fibrocytes
Ibrahim M. Lateral geniculate lesions causing
Nov;34(11):2250-8.
and thyroid-associated ophthalmopathy. Nat
reversible blindness in a pre-eclamptic patient
Rev Endocrinol. 2015 Mar;11(3):171-81.
with a variant of posterior reversible encepha-
Tanaka TS, Elner VM, Demirci H. Solitary
lopathy syndrome. J Neuroophthalmol. 2014
epibulbar neurofibroma in older adult patients.
Dec;34(4):372-6.
Cornea. 2015 Apr;34(4):475-8.
of genome-wide association studies identi-
Stem MS, Hood CT. Salzmann nodular degen-
Tausif HN, Johnson L, Titus M, Mavin K, Chan-
fies novel loci that influence cupping and the
eration associated with epithelial ingrowth af-
drasekaran N, Woodward MA, Shtein RM,
glaucomatous process. Nat Commun. 2014
ter LASIK treated with superficial keratectomy.
Mian SI. Corneal donor tissue preparation for
Sep;5:4883.
BMJ Case Rep. 2015 Jan;2015.
descemet's membrane endothelial keratoplasty.
Springelkamp H...Richards JE, Moroi SE,
Stem MS, Webster LS, Mian SI. Epithelial
Lichter PR, et al. Meta-analysis of genome-
ingrowth as a cause of pseudohypopyon
Thompson DA, Ali RR, Banin E, Branham
wide association studies identifies novel loci
after descemet stripping automated endothe-
KE, Flannery JG, Gamm DM, Hauswirth WW,
associated with optic disc morphology. Genet
lial keratoplasty. JAMA Ophthalmol. 2015
Heckenlively JR, Iannaccone A, Jayasundera
Epidemiol. 2015 Mar;39(3):207-16.
Apr;133(4):e144538.
KT, Khan NW, Molday RS, Pennesi ME, Reh
Srinivasan PP, Kim LA, Mettu PS, Cousins SW,
Subramanian B, Anand M, Khan N, Khanna
peutic strategies for inherited retinal degenera-
Comer GM, Izatt JA, Farsiu S. Fully automated
H. Loss of Raf-1 Kinase Inhibitory Protein (RKIP)
tion: recommendations from the Monaciano
detection of diabetic macular edema and dry
delays early-onset severe retinal ciliopathy in
symposium. Invest Ophthalmol Vis Sci. 2015
age-related macular degeneration from optical
Cep290rd16 mouse. Invest Ophthalmol Vis
Feb;56(2):918-31.
coherence tomography images. Biomed Opt
Sci. 2014 Aug;55(9):5788-94.
Springelkamp H...Richards JE, Musch DC,
Moroi SE, Lichter PR, et al. Meta-analysis
J Vis Exp. 2014 Sep;(91):51919.
TA, Weleber RG, Zacks DN. Advancing thera-
Express. 2014 Sep;5(10):3568-77.
Undavia S, Briceño CA, Massry GG. QuantiSugar A. The importance of corneal endothe-
fied incision placement for postseptal approach
Stacey AW, Sozener CB, Besirli CG. Hyperten-
lial cell survival after endothelial keratoplasty.
transconjunctival blepharoplasty. Ophthal Plast
sive emergency presenting as blurry vision in
JAMA Ophthalmol. Sep 2015:e1-2.
Reconstr Surg. 2015 Apr 20. [Epub ahead of
a patient with hypertensive chorioretinopathy.
print]
Int J Emerg Med. 2015 Apr;8:13.
41
FACULTY PUBLICATIONS JULY 1, 2014 — SEPTEMBER 30, 2015
Vadlamudi V, Gemmete JJ, Chaudhary N,
Weidmayer SL, Bower AD. Pupillary respons-
Wu CY, Kahana A. Immediate reconstruction
Pandey AS, Kahana A. Transvenous sclero-
es can signal potentially serious problems. Prim
after combined embolization and resection of
therapy of a large symptomatic orbital venous
Care Optom News. 2015 Feb;20(2):8-15.
orbital arteriovenous malformation. Ophthal
varix using a microcatheter balloon and bleomycin. BMJ Case Rep. 2015 Jun 24.
Plast Reconstr Surg. 2015 Apr 20. [Epub
Williams AL, Bohnsack BL. Neural crest de-
ahead of print]
rivatives in ocular development: discerning the
Vadlamudi V, Gemmete JJ, Chaudhary N,
eye of the storm. Birth Defects Res C Embryo
Wu CY, Kahana A. Stereotactic navigation
Pandey AS, Kahana A. Transvenous sclero-
Today. 2015 Jun;105(2):87-95.
with a registration mask in orbital decompres-
therapy of a large symptomatic orbital venous
sion surgery: preliminary results. Ophthal Plast
varix using a microcatheter balloon and
Witkin AJ, Shah AR, Engstrom RE, Kron-Gray
Reconstr Surg. 2015 Feb 11. [Epub ahead of
bleomycin. J Neurointerv Surg. 2015 Jun 29.
MM, Baumal CR, Johnson MW, Witkin DI,
print]
[Epub ahead of print]
Leung J, Albini TA, Moshfeghi AA, Batlle IR,
Sobrin L, Eliott D. Postoperative hemorrhagic
Wu RA, Grand P, Trobe JD. Diagnosis and
Vartanian GV, Li BY, Chervenak AP, Walch OJ,
occlusive retinal vasculitis: expanding the
management of ophthalmic emergencies in the
Pack W, Ala-Laurila P, Wong KY. Melatonin
clinical spectrum and possible association
hospital. Hosp Med Clin. 2014 Jul;3:e409-29.
suppression by light in humans is more sensi-
with vancomycin. Ophthalmology. 2015
tive than previously reported. J Biol Rhythms.
Jul;122(7):1438-51.
2015 Aug;30(4):351-4.
Yao J, Jia L, Khan N, Lin C, Mitter SK, Boulton
ME, Dunaief JL, Klionsky DJ, Guan JL,
Wittes J, Musch DC. Should we test for geno-
Thompson DA, Zacks DN. Deletion of autoph-
Vartanian GV, Zhao X, Wong KY. Using flick-
type in deciding on age-related eye disease
agy inducer RB1CC1 results in degeneration
ering light to enhance nonimage-forming visual
study supplementation? Ophthalmology. 2015
of the retinal pigment epithelium. Autophagy.
stimulation in humans. Invest Ophthalmol Vis
Jan;122(1):3-5.
2015 Jun;11(6):939-53.
Wong SH, Plant GT, Cornblath W. Does treat-
Zhang L, Blachley TS, Weizer JS. Baerveldt
Walch OJ, Zhang LS, Reifler AN, Dolikian
ment of ocular myasthenia gravis with early
250 mm2 glaucoma drainage devices in eyes
ME, Forger DB, Wong KY. Characterizing
immunosuppressive therapy prevent second-
with preexisting scleral buckles. J Glaucoma.
and modeling the intrinsic light response of rat
arily generalization and should it be offered to
2014 Aug 20. [Epub ahead of print]
ganglion-cell photoreceptors. J Neurophysiol.
all such patients? J Neuroophthalmol. 2015 Jul
2015 Sep 23. [Epub ahead of print]
24. [Epub ahead of print]
Wallace DJ, Chau FY, Santiago-Turla C, Hauser
Woodward MA, Ple-Plakon P, Blachley T,
quality of life in patients with glaucoma and
M, Challa P, Lee PP, Herndon LW, Allingham
Musch DC, Newman-Casey PA, De Lott LB,
different perceptions from ophthalmologists. J
RR. Osteogenesis imperfecta and primary
Lee PP. Eye care providers' attitudes towards
Glaucoma. 2015 Sep;24(7):508-14.
open angle glaucoma: genotypic analysis of
tele-ophthalmology. Telemed J E Health. 2015
a new phenotypic association. Mol Vis. 2014
Apr;21(4):271-3.
Sci. 2015;56(8):4680-8.
Zhang S, Liang Y, Chen Y, Musch DC, Zhang
C, Wang N. Utility analysis of vision-related
Aug;20:1174-81.
Wu CY, Archer SM, Kahana A. "Tag-team" orWeidmayer S. Frontal mucocele with intracra-
bital and strabismus surgeries with immediate
nial extension causing frontal lobe syndrome.
reconstruction after tumor excision metastatic to
Optom Vis Sci. 2015 Jun;92(6):e138-42.
the inferior rectus. Ophthal Plast Reconstr Surg.
2015 Feb 3. [Epub ahead of print]
Weidmayer S. Seeing red: how ocular rosacea impacts the cornea. Rev Optom. 2015
Apr;152(4):47-50.
42
EXTERNAL GRANTS AND FUNDING
JULY 1, 2014 — SEPTEMBER 30, 2015
FA CU LTY NA M E P ROJ EC T T IT L E SO UR C E
S. Abcouwer, Ph.D.
Bone Marrow Neuropathy Drives Diabetic Retinopathy; multi-PI
NIH
Regulation of Retinal Cell Death in Diabetes; multi-PI
NIH
Role of Interferon-gamma in the Retinal Neuroinflammatory
ADA
Control of Innate Inflammatory Responses in the Retina; multi-PI
BrightFocus Foundation
CCL2 Trap for Diabetic Retinopathy; multi-PI
Novo Nordisk
D. Antonetti, Ph.D.
Mechanisms of Retinal Vascular Permeability in Diabetes
NIH
The Retinal Microenvironment in Diabetic Retinopathy, NIH
Subcontract with Northwestern University
Novel Therapies to Inhibit Diabetic Retinopathy,
NIH
Subcontract with Case Western University
Discovering Novel Atypical PKC Inhibitors as in vivo Chemical Probes
NIH
Structural Studies of Tight Junction Proteins,
NIH
Subcontract with Pennsylvania State University
Targeting aPKC as a Therapy for Diabetic Retinopathy
JDRF
CCL2 Trap for Diabetic Retinopathy; multi-PI
Novo Nordisk
Jules and Doris Stein RPB Professorship
RPB
S. Archer, M.D.
Ocular Toxicity of Combined Carboplatin and Etoposide Phosphate Intravitreal
The Knights Templar
C. Besirli, M.D., Ph.D.
Injection Therapy (IViT) for Retinoblastoma, Award for Stephen Smith, M.D.
Neuroprotection in Pediatric Retinal Detachment
Foundation, Inc.
NIH
Cryoanesthesia
MEDC
Testing of ONL Compounds in Retinal Cell Apoptosis Models
ONL Therapeutics
Career Development Award
RPB
B. Bohnsack, M.D., Ph.D.
Regulation of Ocular Neural Crest and Its Implications in Congenital Eye Diseases
NIH
Zebrafish Model of Primary Congenital Glaucoma: Understanding CYP1B1
Edward Mallinckrodt Jr. Foundation
Regulation of Eye Development
Career Development Award
RPB
G. Comer, M.D., M.S.
Treatment for Central-Involved Diabetic Macular Edema in Eyes,
NIH/Clinical Trial
Coordinating Center: Jaeb Center for Health Research
Structural and Functional Relationships of the Retina in Diabetic Macular Edema
JDRF
A Natural History Study of Macular Telangiectasia—The MacTel Study
LMRI/Clinical Trial
A Phase 2 Multicenter Randomized Clinical Trial of Ciliary Neurotrophic
LMRI/Clinical Trial
W. Cornblath, M.D.
A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Efficacy M. Del Monte, M.D.
Factor (CNTF) for Macular Telangiectasia Type 2 (MacTel)
A 3-month, Multi-Center, Double-Masked Safety and Efficacy Study of
Travoprost Ophthalmic Solution, 0.004% Compared to Timolol
(0.5% or 0.25%) in Pediatric Glaucoma Patient
Merck Research Labs
& Safety Trial of MK-8931 in Subjects with Mild to Moderate Alzheimer's Disease
Study of Binocular Computer Activities for Treatment of Amblyopia
Alcon Laboratories, Inc.
JAEB Center/NIH/Clinical Trial
43
EXTERNAL GRANTS AND FUNDING
JULY 1, 2014 — SEPTEMBER 30, 2015
FA CU LTY NA M E P ROJ EC T T IT L E SO UR C E
R. Douglas, M.D., Ph.D.
Role of CD40+ Fibrocytes in Thyroid-Associated Ophthalmopathy
NIH
A Multicenter, Double-Masked, Placebo-Controlled Efficacy and Safety Study
River Vision LLC
of RV001, an Insulin-like Growth Factor-1Receptor (IGF-1R) Antagonist
Antibody (fully human), Administered Every 3 Weeks (Q3W) by Intravenous
(IV) Infusion in Patients Suffering from Active Thyroid Eye Disease (TED)
Lew R. Wasserman Merit Award
RPB
S. Elner, M.D.
Multicenter Uveitis Steroid Treatment (MUST) Trial,
NIH/Clinical Trial
Coordinating Center: Johns Hopkins University
Macular Edema Treatment Trials Associated with MUST (META-MUST)
NIH/Clinical Trial
Intravitreal Injections of DE-109 for the Treatment of Active, Non-Infectious Uveitis
Santen Pharmaceutical
P. Fort, Ph.D., M.S.
Progressive Impact of Diabetes on Retinal Neuroprotection by α-CrystallinsNIH
Characterization of Crystallin Proteins Expression in Human Retina: Effect
Regulation of Crystallin Neuroprotective Function in the Retina During Eversight
of Diabetes
Diabetes: Impact on Retinal Ganglion Cell Death
International Retinal Research
Foundation
P. Gage, Ph.D.
Pitx 2: Molecular Mechanisms in Eye Development and Disease
NIH
An Inducible and Rapid Model of Glaucoma in Mice
BrightFocus Foundation
Analysis of Ocular Functions of CHD7 in Mouse Models of CHARGE
CHARGE Syndrome Foundation, Inc.
New Mouse Models of Human CHARGE Syndrome
Eversight
T. Gardner, M.D., M.S.
Metabolic Reprogramming in Diabetic Complications; multi-PI
NIH
Michigan Vision Clinician-Scientist Development Program; multi-PI
NIH
Regulation of Retinal Cell Death in Diabetes; multi-PI
NIH
Genes in Diabetic Retinopathy, Coordinating Center: Jaeb
NIH/Clinical Trial
Prompt Panretinal Photocoagulation (Protocol S), Coordinating Center: Jaeb
NIH/Clinical Trial
Clinical Research Training in Diabetic Macular Edema,
Bayer HealthCare
Award with Vinicius Monteiro de Castro, M.D., Ph.D.
A Diabetic Retinopathy Risk of Progression Calculator
Eversight
Evaluation of Retinal Sensory Neuropathy
JDRF
Diabetic Complications Scientific Challenge
Novo Nordisk
Physician-Scientist Award
RPB
J. Heckenlively, M.D.
Investigation of Autoimmune Anti-Retinal Antibodies in Diabetes
NIH
Center for the Study of Retinal Degenerative Diseases
FFB
Clinical Evaluation of Individuals with X-linked Retinoschisis (XLRS)
FFB and Applied Genetic
A Phase II, Multiple-Site, Randomized, Placebo-Controlled Trial of Oral Valproic
44
NNRI
Acid for Retinitis Pigmentosa
Retinitis Pigmentosa Natural History Study of Patients with the P23H Mutation
Technologies Corp.
of the Rhodopsin Gene
The EMMES Corporation
EXTERNAL GRANTS AND FUNDING
JULY 1, 2014 — SEPTEMBER 30, 2015
FA CU LTY NA M E P ROJ EC T T IT L E SO UR C E P. Hitchcock, Ph.D.
Neuronal Development, Injury and Repair in Retina
NIH
Vision Research Training Program
NIH
B. Hughes, Ph.D.
Core Center for Vision Research (five core modules)
NIH
Ion Conductances in the Retinal Pigment Epithelium
NIH
K.T. Jayasundera, M.D.
Novel Quantification Methods for Fundus Flavoprotein Fluorescence
Eversight
and Lipofuscin Fluorescence to Detect Progression in Stargardt Disease
EyeAnalyze: Automated Identification and Quantification of Changes in
MEDC
Retinal Diseases
Post-Approval Study of the Argus II Retinal Prosthesis System
Second Sight Medical Products, Inc
M. Johnson, M.D.
Efficacy and Safety of Lampalizumab Administered Intravitreally to Patients
Genentech, Inc.
with Geographic Atrophy Secondary to Age-Related Macular Degeneration
A. Kahana, M.D., Ph.D.
A Zebrafish Model of Extraocular Muscle Regeneration
NIH
Investigating the Roles of Retinoic Acid and Thyroid Hormone in the Pathogenesis Alliance for Vision Research
of Thyroid Eye Disease
VISmodegib as Neo-adjuvant for ORBital and Periocular Basal Cell Carcinoma (VISORB) Genentech, Inc./Clinical Trial
RPB
Physician-Scientist Award P. Lee, M.D., J.D.
Michigan Vision Clinician-Scientist Development Program; multi-PI
NIH
Vision Health Initiative - IPA with CDC
NIH
Unrestricted Grant
RPB
Child Vision Care Fund W.K. Kellogg Foundation
M. Lipson, O.D.
Overnight Corneal Reshaping - Quality of Life (OCRQL) Survey Instrument
Bausch & Lomb, Inc.
S. Mian, M.D.
Eye Bank Preparation of Donor Tissue for Descemet’s Membrane Eversight
Endothelial Keratoplasty
In vivo Assessment of a Novel Intraocular Pressure Transducer
MEDC
A Prospective, Multicenter, Post-Approval Study of Vision Care’s Implantable VisionCare Ophthalmic
Miniature Telescope (by Dr. Isaac Lipshitz) in Patients with Bilateral Severe to Profound Central Vision Impairment Associated with End-Stage Age-Related
Macular Degeneration
S. Moroi, M.D., Ph.D.
Aqueous Humor Dynamic Components that Determine Intraocular
D. Musch, Ph.D., M.P.H.
Allergan Pharmaceuticals, Inc./
or Ocular Hypertension Factors Predictive of Rapid Visual Field Loss in Early Glaucoma, NIH
Pressure Variance
The Efficacy and Safety of Bimatoprost SR in Patients with Open-Angle Glaucoma Technologies, Ltd.
Clinical Trial
NIH
Subcontract with Washington University
Statins to Prevent Glaucoma Trial (STOP Glaucoma Trial) Planning Grant; multi-PI
NIH
Assessing the Impact of Glaucoma and Its Treatment on the Person
NIH
45
EXTERNAL GRANTS AND FUNDING
FA CU LTY NA M E JULY 1, 2014 — SEPTEMBER 30, 2015
P ROJ EC T T IT L E SO UR C E
P. Newman-Casey, M.D., M.S. Adherence to Glaucoma Medications
Allergan Pharmaceuticals, Inc.
H. Petty, Ph.D.
Nanoparticle Therapy in Cancer
MEDC
D. Puro, M.D., Ph.D.
Retinovascular Pathophysiology: Focus on Proliferative Retinopathy
NIH
R. Rao, M.D.
Sustaining Early-Born Retinal Neuron Potency from Stem Cells: RPB
An Epigenetic Approach
Targeting EZH2, a Histone Methyltransferase, as a Novel Therapy for
The Knights Templar
Human Retinoblastoma
Foundation, Inc.
J. Richards, Ph.D.
Genetics of Homocycteine Metabolism in Glaucoma
BrightFocus Foundation
A Study of Ocular Aging
Eversight
Mechanics of Intraocular Pressure Increase Associated with
NSF
R. Shtein, M.D., M.S.
Multinational, Collaborative Evaluation of Corneal Confocal Microscopy
Diabetic Neuropathy in Type 1 Diabetes; multi-PI,
Subcontract with Mount Sinai Hospital
Assessment of Dry Eye Symptom Severity (DREAM study), NIH
Subcontract with University of Pennsylvania
Trends in Utilization of Endothelial and Penetrating Keratoplasty for
NIH
as a Surrogate Endpoint for the Identification and Prediction of
Eversight
Treatment of Corneal Endothelial Disease
In vivo Effects of Antiglaucomatous Prostaglandin Therapy on Immune Cells,
Epithelium, and Nerves of the Ocular Surface: A Laser in vivo Confocal
Microscopy Study
MEEI
T. Smith, M.D.
Regulation of Retroocular Connective Tissue
NIH
UM-ACE: ACE Collaborative Project,
NIH
Subaccount with David A. Fox, M.D., Department of Internal Medicine,
University of Michigan
Physician-Scientist Award
RPB
J. Stein, M.D., M.S.
Statins to Prevent Glaucoma Trial (STOP Glaucoma Trial)
NIH
Collaboration on Cost-Effectiveness Analyses--DRCR Network,
NIH
Subcontract with JAEB Center for Health Research
Workforce Assessment of Eye Care Providers
American Academy of Ophthalmology
Impact of Losartan Use on the Risk of Developing Open-Angle Glaucoma
American Glaucoma Society
A Dynamic, Personalized Glaucoma Monitoring Decision Support
Glaucoma Research Foundation
Model Enabled by an Extension of Kalman Filtering Theory
Assessment of the Relation between Medications for Epilepsy and Risk of 46
Genetic Factors; multi-PI
Developing Open-Angle Glaucoma
Harvard University
EXTERNAL GRANTS AND FUNDING
FA CU LTY NA M E JULY 1, 2014 — SEPTEMBER 30, 2015
P ROJ EC T T IT L E SO UR C E
J. Stein, M.D., M.S. (cont.) Do Patients with Vision Loss Use More Healthcare Services
Lighthouse Guild
MEEI
Assessment of the Relation between Medications that Alter Innate Immunity
and Glaucoma
Physician-Scientist Award
RPB
The Epidemiology of Macular Holes and whether Use of Medication
University of California
Containing Estrogen Affect Development of Macular Holes Are Medications Used to Treat HIV and Hepatitis Beneficial in Preventing San Francisco
University of Kentucky
Macular Degeneration
A. Sugar, M.D.
Corneal Preservation Time Study, Coordinating Center: Jaeb
NIH/Clinical Trial
D. Thompson, Ph.D.
Control of Innate Inflammatory Responses in the Retina; multi-PI
BrightFocus Foundation
Center for the Study of Retinal Degenerative Diseases
FFB
Gene-Replacement Therapy for XLRP Due to RPGR Mutations
FFB
Gene-Replacement Therapy for RDH12 Mutations
RDH12 Fund for Sight
J. Trobe, M.D.
Automated Diplopia Assessment System (ADAS); multi-PI,
Medar Corporation/Michigan
Award with Lindsey De Lott, M.D.
Corporate Relations Network
K. Wong, Ph.D.
Physiology of Intrinsically Photosensitive Rentinal Ganglion Cells
NIH
Ameliorating the Condition of the Blind through Melanopsin
Alliance for Vision Research
Neural Circuits and Synapses for Early Visual Processing
US Department of Defense-Army
M. Woodward, M.D.
Telemedicine For Anterior Eye Diseases
NIH
D. Zacks, M.D., Ph.D.
Autophagy and Control of Photoreceptor Apoptosis
NIH
Autophagy and Control of Photoreceptor Cell Death in Autosomal Dominant Bayer HealthCare
Retinitis Pigmentosa
Center for the Study of Retinal Degenerative Diseases
FFB
Dysregulaton of RPE Autophagy and Age-related Macular Degeneration
RPB
SOURCE ABBREVIATIONS
ADA ...... American Diabetes Association
NIH ....... National Institutes of Health
FFB ....... Foundation Fighting Blindness
NNRI ..... National Neurovision Research Institute
JDRF ..... Juvenile Diabetes Research Foundation International
NSF ....... National Science Foundation
MEEI ..... Massachusetts Eye and Ear Infirmary
RPB ....... Research to Prevent Blindness
MEDC .... Michigan Economic Development Corporation
47
W.K. KELLOGG EYE CENTER FACULTY, FELLOWS, AND RESIDENTS 2015
All of us at the Kellogg Eye Center are
committed to improving lives through curing,
preventing, and treating eye disease.
Faculty of the Department of
Ophthalmology and Visual Sciences
First row (left to right):
Sejal Amin, M.D., Melisa Nika, M.D., Courtney Kauh, M.D., M.S.,
Paul Lichter, M.D., M.S., Michael Smith-Wheelock, M.D., H. Kaz Soong, M.D.,
Alan Sugar, M.D., Monte Del Monte, M.D., Paul Lee, M.D., J.D.,
Christine Nelson, M.D., Denise John, M.D., Mark Johnson, M.D.,
Shahzad Mian, M.D., Thomas Gardner, M.D., M.S., Donna Wicker, O.D.,
Dolly Padovani-Claudio, M.D., Ph.D., Shannon Joseph, M.D.
Second row (left to right):
Joshua Stein, M.D., M.S., Matthew Manry, M.D., Rajesh Rao, M.D.,
Anjali Shah, M.D., Paula Anne Newman-Casey, M.D., M.S., Gale Oren, M.I.L.S.,
Kari Branham, M.S., Naheed Khan, Ph.D., Dongli Yang, M.D., Ph.D.,
Kwoon Wong, Ph.D., Patrice Fort, Ph.D., M.S., David Musch, Ph.D., M.P.H.,
Alon Kahana, M.D., Ph.D., César Briceño, M.D., Cagri Besirli, M.D., Ph.D.,
Stephen Smith, M.D., Grace Wang, M.D., Ph.D., Catherine Choi, M.D.,
Sophia Wang, M.D., Marina Eisenberg, M.D., Fatemeh Rajaii, M.D., Ph.D.
Third row (left to right):
Karen Christopher, M.D., Stephen Odaibo, M.D., Hakan Demirci, M.D.,
Daniel Kasprick, M.D., Sara Weidmayer, O.D., Zvi Kresch, M.D.,
Cheng-mao Lin, Ph.D., Roni Shtein, M.D., M.S., Courtney Dewey, O.D.,
Elizabeth Du, M.D., Abigail Fahim, M.D., Ph.D., Wayne Cornblath, M.D.,
Amy Lagina, O.D., K. Thiran Jayasundera, M.D., Sherry Day, O.D.,
Lee Kiang, M.D., Ph.D., Neil Farbman, M.D., J.D., Steven Cohen, M.D.
Fourth row (left to right):
Angela Elam, M.D., Krista Stewart, M.D., Daniel Albertus, M.D.,
Shivani Gupta, M.D., Donald Puro, M.D., Ph.D., Bradley Taylor, O.D., M.P.H.,
Christopher Gappy, M.D., Karen DeLoss, O.D., Susan Elner, M.D.,
Theresa Cooney, M.D., Joshua Vrabec, M.D., Steven Archer, M.D.,
Lindsey De Lott, M.D., Rebecca Wu, M.D., Ariane Kaplan, M.D.,
Monica Michelotti, M.D., Kevin Tozer, M.D., Devon Ghodasra, M.D.
Fifth row (left to right):
Daniel Sand, M.D., Marius A. Tijunelis, M.D., M.B.A., Terry Smith, M.D.,
John Heckenlively, M.D., Paul Grenier, O.D., Steven Abcouwer, Ph.D.,
Terry Bergstrom, M.D., Gary Sandall, M.D., M.S., Bret Hughes, Ph.D.,
Philip Gage, Ph.D., Grant Comer, M.D., M.S., Jonathan Greene, M.D.,
Jerome Finkelstein, M.D., Helios Leung, O.D., Ph.D., Andrew Stacey, M.D., M.S.,
Maxwell Stem, M.D., David DeMill, M.D., Andrew Lewis, M.D.,
Kristopher Kowal, M.D.
For a complete listing of our faculty, visit:
www.kellogg.umich.edu/about/faculty_bios.html
Our guiding principles are teamwork, caring,
innovation, and integrity.
Executive Officers of the University of Michigan Health System
Marschall S. Runge, M.D., Ph.D.
Executive Vice President for Medical Affairs and Dean
of the Medical School
David A. Spahlinger, M.D.
Executive Vice Dean for Clinical Affairs and President
of the Hospitals, Health Centers, and U-M Medical Group
T. Anthony Denton, J.D., M.H.A.
Senior Vice President and Chief Operating Officer for
the Hospitals, Health Centers, and U-M Medical Group
The Regents of the University of Michigan
Michael J. Behm, Mark J. Bernstein, Laurence B. Deitch,
Shauna Ryder Diggs, Denise Ilitch,
Andrea Fischer Newman, Andrew C. Richner,
Katherine E. White, Mark S. Schlissel (ex officio)
Editor: Jonathan D. Trobe, M.D.
Writers: Aimee Bergquist, Barbara Sefton
Editorial Assistant: Lisa Burkhart
Design and Art Direction: David Murrel
Photographers: Eric Bronson, Daryl Marshke, Scott Soderberg,
Austin Thomason, Michigan Photography; Amber Schultz,
U-M Department of Ophthalmology and Visual Sciences
FOR PATIENT APPOINTMENTS, PLEASE CALL 734.763.8122
For additional copies, please contact us:
University of Michigan
Department of Ophthalmology and Visual Sciences
W.K. Kellogg Eye Center
1000 Wall Street
Ann Arbor, Michigan 48105
734.763.4660 • www.kellogg.umich.edu
University of Michigan
W.K. Kellogg Eye Center
Department of Ophthalmology
and Visual Sciences
1000 Wall Street
Ann Arbor, MI 48105
Kellogg Among Nation’s
Best in Eye Care
10
#
OPHTHALMOLOGY
IN THE NATION
The University of Michigan Kellogg Eye Center is proud to be
ranked #10 in the country by U.S. News & World Report for
being among the nation’s best in providing outstanding care
for the most complex eye conditions.
Kellogg has seen extraordinary growth in all aspects of patient
care, research and education since the department was established in 1872. Every day, our clinicians, scientists, trainees
and staff work together to shape the future of eye care and
vision science. The Kellogg team is especially proud of these
recent accomplishments:
• Kellogg retinal surgeons performed the first four surgeries in the United States to implant an artificial retina, or “bionic eye,” since the FDA approved the device in 2013.
2015 U.S. NEWS & WORLD REPORT’S “BEST HOSPITALS”
•
Kellogg scientists received $14M in research funding in FY 2015, with $6.8M coming from the National Institutes of Health (NIH). This ranks Kellogg #10 in NIH funding among U.S. eye institutions.
•
Kellogg is one of the top eye centers in the world for training the next generation of physician-scientists. In 2015, Doximity ranked Kellogg’s residency program #8 in reputation and #6 in research output.